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ABSTRACT
Nosocomial infections associated with implanted medical- devices are on the rise due to a growing
immunocompromised patient population. The organisms of interest in this study are
Pseudomonas aeruginosa and Candida albicans. These organisms are opportunistic pathogens
and are frequently implicated as the cause of infection and colonization of medical devices. P.
aeruginosa is a motile gram-negative bacterium that is able to suppress the growth of C. albicans.
Quourm sensing mimicry and biofilm formation on the hyphal surface of C. albicans by P.
aeruginosa aids in suppression. C. albicans is a dimorphic fungus capable of quorum sensing
with E,E-farnesol and is a central focus in this work. The goal of this project is to determine
changes in protein expression when P. aeruginosa is exposed to E,E,-farnesol using 2D DIGE®.
Changes in the cytosolic proteome of P. aeruginosa expose metabolic shifts that result in
suppression of C. albicans. This work summarizes the effect of growth phase and concentration
of E,E-farnesol on P. aeruginosa PAO1 and GSU3. Preliminary results reveal a general response
of P. aeruginosa to C. albicans as changes in relevant metabolic nodes that affect pyocyanin
production and the induction of virulence factors that lead to the killing of C. albicans. The
overall goal of this study was to generate a profile of protein expression where a variety of
conditions to further characterize the response could be easily assayed.
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Introduction
The goal of this dissertation was to explore through the use of expression proteomics the
dynamic interplay that occurs between P. aeruginosa and C. albicans. Both of these organisms
are important opportunistic pathogens in the health-care setting. P. aeruginosa is most notably
associated with Cystic Fibrosis patients, in whom it is one of the leading causes of chronic lung
infections and death due to damage to the lung tissue (Gilligan, 1991). Infections caused by C.
albicans are most notably associated with patients undergoing cancer treatment, diabetes
mellitus, or infection with human immunodeficiency virus (Kao, et al., 1991). Both of these
microorganisms warrant study due to the significant roles they play in device associated
nosocomial infections. The variety of infections attributed to these two organisms are linked to
the type of indwelling medical- device in place within the patient. Device types such as centralvenous catheters, urinary catheters, and mechanical ventilators are commonly colonized and the
type of disease they cause is directly linked to the insertion site of the device. For example,
blood-stream infections resulting from the colonization of central-venous catheters to ventilatorassociated pneumonia in patients requiring mechanical respiration (Pierce, 2005).
A third compelling reason to study the interplay of these organisms is based on clinical
data that suggests that P. aeruginosa and C. albicans may suppress the growth and virulence of
one another through a variety of mechanisms (Kerr, 1994; Burns, 1999). A thorough
understanding of this complex relationship has the potential to better prevent infections by
exploiting the well-developed tactics used by Pseudomonas and Candida for controlling growth
and virulence of competing microorganisms
1

Background

Nosocomial medical-device associated infections:
Approximately two million nosocomial infections occur each year (Halye, 1985; Bunting,
2005), accounting for roughly 5% of all patients admitted into a hospital resulting in 90,000 to
100,000 deaths annually in the United States (Buntin, 1999; Starfield, 2000). Antibiotic resistant
organisms cause approximately 70% of nosocomial infections and the remaining 30% are caused
by infections associated with indwelling medical devices (Safdor, 2001; Burke, 2003).
Installation of a urinary catheter, composed of medical grade materials including silicone and
latex, is inserted into the urethra until the tip of the catheter reaches the bladder. Upon insertion it
is possible to introduce microorganisms from the external surface of the urethra into the deeper
and sterile regions of the urinary tract. If there is a urinary tract infection already in progress at
the time of insertion, the catheter surface may allow the organisms to penetrate further into the
urinary tract or provide a substrate for biofilm formation. Approximately 40% of nosocomial
infections are catheter associated urinary tract infections (CAUTI). In the United States, one
million cases of UTI were reported, of which 80% were classed as CAUTI.
The Edmond M. SCOPE project (1995-2002) (Wisplinghoff, et al., 2004) identified the
causative agents of blood-stream infections (BSI) and ranked them according to rate of
incidence. Candida species were the fourth most common isolate, responsible for 9% of total
patients and P. aeruginosa was the seventh most common isolate, responsible for 4.3% of total
2

patients with a sample size in this study of 20,000 patients. The prevalence of these two
organisms in association with multiple device types and a robust ability to form biofilm on
medical grade materials are two major reasons for the focus of this study.
Historically, the medical community has viewed hospital- acquired infections as a normal
part of medical practice. The perception pervaded that infections of this type were inevitable
resulting from immunologically suppressed patients with non-communicable diseases.
Innovative medical technology has lead to increased reliance on the use of medical devices and
treatment strategies that suppress the immune system. The rate of nosocomial infections and
deaths related to these infections increased to the point that questions were asked as to their
source. This drew a great deal of scrutiny on the health care delivery system from government
regulators, the CDC, private insurance companies, and the general public.
Epidemiological data has provided information about how non-communicable diseases are
commonly spread by the health care worker among immunologically suppressed patient
populations. This data has transformed the perception that non-communicable infections among
hospital patient populations are inevitable into one where nosocomial infections are preventable.
Gerberding reported this shift in attitude in 2002 as one of many papers aimed determining the
suspected origins of this infection type and approaches towards mitigating the incidence of
nosocomial infections.
Nosocomial infections, or health-care setting acquired infections, are the fourth leading
cause of death in the United States, following stroke, cancer, and heart disease. Adding to the
staggering death toll related to nosocomial infections is the high financial cost. In 2002, $6.5
3

billion dollars were spent to treat nosocomial infections and were paid in large part by third party
payers, such as Medicare or private insurance companies. (Weinstein, 1998; Jarvis, 2001) In
Pennsylvania, the treatment of nosocomial infections cost Medicaid and the State Employee’s
Benefits plan $125 million dollars and private insurance companies $1 billion dollars (Buntin,
2005). In 2007, the New York Times reported that Medicare would no longer pay for the
treatment of nosocomial infections after October 2008, as a part of the pay for performance
policy that makes health care facilities responsible for the delivery of good health care
(Glickman, et al., 2007). In a statement to congress by Mike E. Miller, Ph.D. on behalf of the
Medicare Payment Advisory Commission in July 2005, he states the ultimate goal of the pay for
performance program is to remove the inequity of equal payment to physicians that provide
inadequate care to those who meet or exceed patient needs.
Research has shown that simple changes, like hand washing, improved cleaning protocols
of common-use equipment, and improved environmental controls within the health-care
environment can play a drastic role at reducing the incidence of nosocomial infections.
Professional organizations such as the Association for Professionals in Infection Control and the
Society for Healthcare Epidemiology of America include as a part of their mission statement to
educate medical professionals and collect accurate data on the incidence of nosocomial infection.
It is crucial to posses a thorough understanding of the biology of the microorganisms that
cause device-associated nosocomial infections in order to design effective treatment strategies.
In an early study by Elek and Conen published in 1957, it was shown that the inoculum size of a
pathogen required to cause infection was much lower when a foreign body, such as a medical
device, was present. This work suggested that the presence of the medical device compromises
4

the primary and secondary defenses of the immune system so that fewer invading organisms are
needed to cause an infection. Treatment strategies designed for traditional infections, that do not
include the presence of a foreign body, are highly ineffective when an implanted medical-device
is present.
Indwelling medical devices present an ecological niche that may be exploited by
microorganisms. Major factors that play a role in the incidence of medical -device associated
infections include the materials used in the device’s construction, the breach of anatomical
barriers at the point of placement within the patient, and the type of coatings applied to the
device surface (Stone, et al., 1999; Ramage, et al., 2006; Backovic, et al., 2007). The materials
used in the construction of medical devices are commonly medical grade latex or silicone. These
materials provide a prime substrate that is permissive for the adhesion of host proteins and in the
primary attachment of microorganisms that lead to biofilm development. It has been
documented that the initial deposition of host proteins on the device surface plays an important
role in facilitating the attachment of microorganisms to the device surface (Denstedt, 1998;
Trautner, 2004). A second significant factor in the role that medical devices play in the
incidence of infection is the breach in primary anatomical barriers that normally prevent entry of
microorganisms into sterile regions of the body such as the blood stream, lungs, or bladder
(Trautner, et al., 2004).
Shortages in medical staff have been implicated as one possible reason for the
oversight of urinary catheters left in place for extended periods of time. A vicious cycle is
created where more patients become critically ill from devices left in place beyond the
recommended period of use thus, requiring more care and more attention from the medical staff
5

when the infection could have been prevented. Once an infection has developed in association
with the abiotic surface of the medical device these colonizing organisms become extremely
difficult to treat with traditional antibiotics. In fact, antibiotics are regarded as one of the least
effective methods to treat all types of devices associated infections (Trautner, et al., 2004). The
method, recommended by the Centers for Disease Control, to treat these infections involve the
removal of the medical devices at regular intervals after 72 hours of use. Due to the refractory
nature of microorganisms within a biofilm on the surface of an implanted medical-device to
antibiotic therapy the device must be removed and replaced if medically necessary to aid is one
major reason to remove the device. It was reported by Kojic et al. in 2004 that if a device is not
removed it is possible for the infection to reoccur once antibiotic therapy is complete.
Timely removal is another essential element to tackling the problem associated with
nosocomial medical-device associated infections. Astonishingly, in a study by Saint et al., 2000,
that was directed at identifying the number of non-essential urinary catheters it was reported that
23% of doctors involved in the project did not accurately report which of their patients had
urinary catheters in place and how long they were in use. To obtain this data medical students,
residents, and attending physicians were each asked which of their patients did or did not have
urinary catheters in place. It was possible to quantify how many urinary catheters were
inaccurately reported by comparing the response of the doctor to a computer database that
tracked the status of each patient.
In summary, medical-device associated nosocomial infections present a high cost both
financially and for patient mortality. It has been shown with epidemiological data that a wide
variety of microorganisms play a role in causing these infections that can originate from the
6

normal flora of the patient or can be carried by the health care facility or health care worker.
Multiple approaches have been taken to mitigate the incidence of these infections by improving
maintenance of the health care facility, procedures for installing and maintaining the medical
devices, and improved surveillance of susceptible patient populations.
Quorum sensing
Quourm sensing is the process by which bacteria and some fungi detect how many
microorganisms are present in the surrounding environment. Then dependent on the number of
surrounding microorganisms gene expression is altered in order to coordinate gene expression
among the microbial community. Known quorum-sensing compounds are chemical compounds
such as acylated homoserine lactones (acyl-HSLs), oligopeptides, butyrolactones, furanosyl
diester autoinducer-2 (AI-2), and the quinolone signal in P. aeruginosa known as PQS (Calfee,
et al., 2001; Diggle, et al., 2003; Smith, et al., 2003).
The concentration of the quorum- sensing molecule in the external environment is directly
proportional to the number and density of the group at large within a given space. As the
population density increases so too does the concentration of the quorum- sensing compound.
The central theme of quorum sensing is based on the secretion of signaling molecules by
multiple producing organisms into the external environment. Once the signaling molecule
reaches a threshold concentration at the point of the effector cells, which can be the same or a
different species from the producing organisms. The effector cells then alter their gene
expression resulting in community wide alterations in phenotype. Generally, the phenotypic
traits altered are involved in virulence and biofilm development.
7

The processes by which the quorum- sensing compound can interact with the target cell are
diverse among different species of microorganisms. The three major mechanisms identified are
passive diffusion, active transport (Smith, et al., 2003; Hogan, 2006) and a sensor kinase
cascade, as is the case with Vibrio harveyi and Vibrio cholerae (Taga, et al., 2001). Once these
compounds reach a threshold level, regardless of their mechanism of entry, within the cell they
influence gene expression.
Initially, quorum sensing was thought to only occur between single species; however, it
has been shown that in mixed-species populations quorum- sensing signaling molecules exhibit
cross talk (Vlamakis, et al., 2005). Experiments have shown that concentrations are altered
resulting in one bacterial species affecting the gene expression in a different species. This was
shown to be the case in co-cultures of E. coli and V. cholerae, two organisms that both utilize
autoinducer 2 (AI-2) signals. V. cholerae would produce the signal and E. coli would uptake the
AI-2 molecule causing a change in concentration of AI-2 in the external environment and
altering gene expression in V. cholerae (Xaiver, et al., 2005). Interestingly, P. aeruginosa
produces virulence factors in response to AI-2 when it does not produce AI-2 itself (Vlamakis, et
al., 2005). Quorum sensing cross-talk increases the complexity of interactions between mixedspecies populations. The ability of one microorganism to alter the gene expression of another
through quorum sensing presents potential targets for mitigating pathogenesis in organisms that
rely on quourm sensing to regulate the expression of virulence factors. The ability to jam the
signals and prevent the expression of virulence factors may be another approach to combat
difficult to treat or antibiotic resistant infections.

8

Interaction between P. aeruginosa and C. albicans
The selection of P. aeruginosa and C. albicans as the central focus of this work was based
on patterns of microbiological colonization of the lungs of Cystic Fibrosis patients. Cystic
Fibrosis is a genetic disorder that affects approximately 30,000 Caucasian Americans (Lau, et
al., 2004). Cystic Fibrosis is characterized by a defect in the CFTR transport system that is
normally responsible for the secretion of chloride ions across the apical surface of secretory cells
throughout the body. In individuals that have a defective CFTR channel the amount of chloride
ions secreted by the cell is low (Hassett, et al., 2002). The osmotic pressure created by this
defect in ion transport induces the formation of thick mucous within the lumen of the airway.
Water is retained within the cell and is not properly secreted with the secreted mucous. This has
the effect of disrupting one of the primary defense barriers in the lung to capture invading
microorganisms and clear them. The cilia that normally remove airway mucous are unable to
properly function in clearance because the thick, viscous mucous prevents their movement.
Historically, CF patients have had digestive problems where viscous mucous also
accumulated within the secretory ducts and lumen of the small intestine of the digestive tract
resulting in poor adsorption of nutrients, in addition to lung infections. Changes in diet that
restricted salt were able to mitigate the effects of CF on digestion, improving the ability of
patients to obtain nutrients and increased the life expectancy of many CF patients. Also,
antibiotics to prevent bacterial infections from progressing within in the lung prolonged the life
of most CF patients from an average of 10 years to 25 years of age (Govan, et al., 1993).
The primary cause of death in Cystic Fibrosis patients remains to be lung damage resulting
9

from chronic infections caused by P. aeruginosa. This organism remains to be responsible for
80% of the premature deaths in this patient population due to a progressive loss of pulmonary
function. Chronic lung damage is caused by repeated inflammation events in response to
bacterial antigens released from chronic biofilms of predominantly mucoid P. aeruginosa
colonies (Gilligan, 1991; Lau, et al., 2004). Current therapy for P. aeruginosa infections in CF
patients relies on the combination of different classes of antibiotics. These combinations are
typically an aminoglycoside and anti-Pseudomonal Beta-lactams or the use of an aminoglycoside
with fluroquinolone. Tobramycin inhaled directly into the lung has been extremely effective in
delivering high doses of the drug to the infected areas while keeping the incidence of side-effects
low (Hassett, et al., 2002).
Regular monitoring of the microbiological profile of CF sputum has been an important
clinical tool to best improve the administration of antibiotics to control rates of infection. From
these patient profiles it has been possible to collect statistical data on the rate of clearance of
significant pathogens from the lung. This information has revealed an interesting trend in the
patterns of colonization by fungal organisms. Typically, in non-CF patients with compromised
lung tissue that receive antibiotic therapy an upsurge in the number of isolates of fungal species,
most commonly C. albicans occur. Interestingly, in Cystic Fibrosis patients where the tissue is
compromised and should be favorable for colonization by fungal species this trend is lower than
expected.
Data that C. albicans is the second most common organism isolated from sputum in adult
CF patients suggests that it is not adept at persisting in the CF lung (Table 1). C. albicans
isolates demonstrate patterns of appearance and disappearance. This suggests that C. albicans
10

repeatedly enters the lung but is cleared before a persistent colonization can occur. An upsurge
in C. albicans colonization is only apparent when the CF patients with chronic P. aeruginosa
infections undergo anti-pseudomonal antibiotic therapy. In a study by Burns, et al. in 1999 the
sputum of CF patients was tested before, during, and after antibiotic therapy. It was found that
while the number of P. aeruginosa isolates decreased the number of C. albicans isolates
increased. This finding suggests P. aeruginosa is modifying the environment in the CF airway
to inhibit of growth in C. albicans. In a study by Kerr in 1994 it was found that P. aeruginosa
and Burkholderia cepacia were able to inhibit the growth of C. albicans and various fungal
species, including Aspergillus niger, Cryptococcus neoformans, and Histoplasma capsulatum.
These fungal species were not inhibited by the commonly isolated lung pathogens Escherichia
coli NCTC 10418, Staphylococcus aureus NCTC 6571, and Haemophilus influenzae NCTC
11931 (Tripathi, et al., 1969).

11

Table 1: Microbiological profile of adult Cystic Fibrosis patients

per ml aspirate

Table 1: Bauernfeind, et al., 1987 Infection vol. 15. The persistence rate is determined by how
frequently isolates are verified from consecutive analyses of sputum.

P. aeruginosa and C. albicans represent an interesting model system for antagonistic
bacterial-fungal polymicrobial biofilms (Hogan, et al., 2002; Semighini, et al., 2006). Clinical
data has revealed that infections by these organisms tend not to occur concurrently but
sequentially. In the host, P. aeruginosa is able to suppress the outgrowth of C. albicans and
allow for clearance of the fungi by the immune system. However, if anti-pseudomonal
antibiotics are administered the number of P. aeruginosa isolates decline and isolates of C.
albicans increase (Kerr, 1994; Burns, et al., 1999).
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Figure 1: Interaction between C. albicans and P. aeruginosa

Figure 1: (Source Hogan, et al., 2002) The interactions that occur between C. albicans
and P. aeruginosa according to the morphological properties of Candida.
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Candida and Medical-Devices

C. albicans is a dimorphic yeast that is a member of the normal flora of humans that is
acquired early in life commonly during the passage through the birth canal or from close contact
with family members (Odds, 1988). The ability of C. albicans to colonize mucosal surfaces and
penetrate epithelial tissue is dependent on dimorphic shifts. The dimorphism of C. albicans can
be defined as an environmentally controlled reversible transition between yeast and a mycelial
form. Dimorphism has been shown to rely on initial cell density; this phenomenon is defined as
the inoculum size effect and is one of eleven factors that lead to dimorphic shifts (Kulkarni, et
al., 1981).
Biofilm formation is a major factor in the pathogenic process for this organism that
allows for the colonization of mucosal surfaces, dentures, and medical devices. The initial stages
of biofilm formation rely on the ability of C. albicans to regulate its morphology. What makes C.
albicans of special concern is its ability to exhibit dimorphism during the biofilm formation
process (Jabra-Rizk, et al., 2004). Physiological regions of the human body where C. albicans
commonly colonize include the mouth, vagina, lungs, intestine, bronchi, skin, heart, meninges,
bones, and joints. The biofilm of C. albicans begins on the mucosal surface in the yeast form
and once dimorphism has initiated hyphae are formed and this organism is able to penetrate into
tissues and gain access to virtually any physiological region of the body, resulting in systemic
candidiasis.

14

Figure 2: Stages of biofilm formation in C. albicans
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(Source: Jabra-Rizk, et al., 2006 FEMS Yeast Res vol. 6)
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P. aeruginosa is thought to inhibit growth and the ability of C. albicans to cause a
nosocomial infection in patients with a medically implanted device. The exact mechanism of
this inhibition is unclear although quorum-sensing molecules are thought to play a role (Pierce,
2005). Supported by data that shows when an antibiotic to suppress a Pseudomonas infection is
given, a Candida infection soon follows (Burns, et al., 1999). This report states that with the use
of inhaled antibiotics the number of P. aeruginosa isolates decrease and the number of isolates of
C. albicans increases. The author does not consider C. albicans to be a concern for CF patients
as a pulmonary pathogen. However, in the NNIS report from May 1999, C. albicans is
responsible for 4.7% of nosocomial pneumonias.
Candida infections are difficult to diagnose definitively to the species level when
associated with an implanted medical device. As more standardized and sophisticated diagnostic
tests emerge it is possible to better identify Candida species as the causative agent of a deviceassociated infection. The resultant trend of the use of more accurate diagnostic tools is an
increasing incidence of Candida species as the cause of device-associated nosocomial infections
(Kojic, et al., 2004). Data reported in a NNIS study period from 1986 to 1989 reported the
isolation of Candida species from urinary isolates of patients in the ICU at 22.1%. In the study
period from 1992 to 1997 the rate of urinary isolates from ICU patients was at 31%. The
presence of the urinary catheter is a significant factor in the occurrence of this type of infection.
It was also reported in the NNIS study that in ICU patients with a urinary catheter 21% of the
infections were caused by Candida species. In ICU patients without a urinary catheter in place
only 13% of patients had urinary tract infections caused by Candida species. Other risk factors
that play a role in Candida growth in the urine include diabetes mellitus, urinary tract
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abnormalities, malignancy, and antibiotic use (Kojic, et al., 2004).
Farnesol is secreted by C. albicans continuously and functions to control of the
morphological state of the entire cell population. The trans, trans conformation was shown to be
biologically relevant. P. aeruginosa also secretes an analog of farnesol, 3-oxo-C12-HSL
(Hogan, et al., 2004). This compound is biologically active in C. albicans and is able to inhibit
hyphal formation and further biofilm development. The ability of P. aeruginosa to mimic this
signal causes the morphology of C. albicans to remain in the yeast form. This has the effect of
reduced efficiency in forming a biofilm on a variety of surfaces including medically implanted
devices (Nickerson, et al., 2006). Based on this mechanism the goal of P. aeruginosa is to not
kill the C. albicans cell but to inhibit its ability to form biofilms. However, P. aeruginosa does
have the ability to kill hyphal form C. albicans by physically attaching to the hyphal element and
using enzymatic methods to lyse and kill the cell (Hogan, et al., 2002).

P. aeruginosa and Pyocyanin

P. aeruginosa is a ubiquitous gram-negative bacterium and is a member of the normal
human microbial flora. Pseudomonas aeruginosa does not become a serious threat as a pathogen
until the host immune system is suppressed or if a biofilm has the opportunity to develop.
Suppression of the host immune system can be due to multiple factors including infection with
Human Immuno-Deficiency virus (HIV), chemotherapy, burns, transplants, implanted medical
devices, and neutropenia. In the compromised host P. aeruginosa is commonly associated with
infections of the mucosa and respiratory tract that are difficult to treat and frequently lead to
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death (Dickinson, et al., 1989). Once in a biofilm, this organism becomes highly resistant to
chemothereputic agents due to phenotypic and environmental changes related to the biofilm
including reduced growth rate, reduced oxygen tension, and the initiation of membrane efflux
pumps that are genetically regulated.
Pyocyanin (PCN) is a secondary metabolite that is produced by P. aeruginosa. This
compound is a zwitterion that easily penetrates biological membranes and has been found in
large concentrations from the sputum and ear-secretions of patients infected with P. aeruginosa.
PCN is a compound that is a very important virulence factor and is regulated by the Las/Rhl
quorum-sensing system. In infected human host tissue, PCN causes cellular damage, inhibition
of respiration, inhibition of ciliary function, epidermal cell growth, procyclin release, calcium
homeostasis, and the inactivation of alpha-1-protease inhibitor. The inactivation of this inhibitor
adds to the imbalance of protease-antiprotease activity that is common in the CF lung. PCN and
the precursor phenazine-1-carboxylic acid have also been found to alter the host immune
response by modulating levels of RANTES and IL-8 (Lau, et al., 2004).
The antimicrobial action of PCN is dependent on the presence of oxygen (Hassan, et al.,
1980). The first stage of PCN antimicrobial activity requires the reduction of PCN to its
monovalent or divalent form. PCN must then auto-oxidize in order to continue the process.
Interestingly, PCN is able to inactivate the anti-oxidative stress mechanisms catalase and the
GSH redox cycle in human epithelial cells (Lau, et al., 2004). In the report by Westwater, et al.
in 2005, the ability of C. albicans to protect itself from oxidative stress by secreting E,E-farnesol
into the surrounding environment was established. The protective mechanisms of farnesol
against oxidative damage could potentially be one mechanism to resist attack by P. aeruginosa
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and mitigate the harmful effects of PCN.
P. aeruginosa is able to infect a variety of hosts from different phylogenetic backgrounds
including humans, plants, nematodes, and insects. Interestingly, the virulence mechanism
utilized by P. aeruginosa in such divergent hosts is largely the same. The benefit of this broad
range of host susceptibility with similar virulence mechanisms is the availability of model
organisms that are relevant to the human host. PCN is one of the major virulence mechanisms
used in all of the hosts that P. aeruginosa is known to infect. The nematode Caenorhabditis
elegans virulence assay is very useful to better understand the virulence mechanisms used by P.
aeruginosa. The main mechanism used by P. aeruginosa to kill C. elegans is through the
generation of reactive oxygen species by PCN (Tan, 2000). The C. elegans assay can be used to
assess two different virulence mechanisms. The fast killing assay is based on the activity of
PCN. This assay is based on an accumulation of PCN and requires eight hours to kill the
animals. The slow killing assay is based on the ingestion and growth of P. aeruginosa in the
lumen of the gut of C. elegans. Killing occurs after several days when P. aeruginosa is able to
penetrate the epithelium and kill the worm (Tan, 2000).
The mechanism used by PCN to induce cellular damage has lead to the development of
new treatment strategies for CF patients chronically infected with P. aeruginosa. It has been
found that treatment regimens that utilize GSH aerosols and anti-oxidant supplements have
improved CF lung functions. Another potential clinical application is to prevent the production
of PCN by targeting the enzymes that are a part of the enzymatic pathway that lead to its
production. P. aeruginosa synthesizes PCN from the shikimate pathway (aro pathway). The
shikimate pathway is used to synthesize aromatic amino acids, para-aminobenzoic acid, vitamin
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K, folic acid, and ubiquinone. This pathway is found in bacteria, yeasts, filamentous fungi,
apicomplexan parasites, plastids of plants, and alge. Vertebrates do not possess the enzymes used
in this biosynthetic pathway and must acquire the nutrients synthesized through diet (Lau, et al.,
2004). The enzymes of the shikimate biosynthetic pathway are a potential target for
antimicrobial drugs and also a vaccine target to prevent production of PCN.

Figure 3: Regulatory pathway for the biosynthesis of pyocyanin
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Figure 3: (Source: Lau, et al., 2004 Trends in Molecular Medicine vol. 10)

Farnesol
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Figure 4: Molecular structure of E, E-farnesol

Figure 4: Molecular structure

Farnesol, a sesquiterterpenoid, is present in essential oils such as citronella, neroli,
cyclamen, lemon grass, tuberose, rose, musk, and balsam. Trans, trans-farnesol (E,E-farnesol) is
synthesized through the ergesterol biosynthetic pathway in Candida albicans. E,E-farnesol is
derived from farnesyl pyrophosphate, a compound integral to the lipid biosynthetic pathway.
Four isomers of farnesol are produced but only trans, trans isomer is biologically active
(Shchepin, et al., 2003). E,E- farnesol has been isolated from the spent medium of C. albicans
by extraction with organic solvents and identified using gas chromatography-mass spectrometry
as 1-hydroxy3,7,11-trimethyl-2,6,10-dodecatriene (Hornby, et al., 2001)
The synthesis of farnesol begins at the generation of the isoprene unit isopentenyl-PP and
deimethylal-PP. These two compounds are oriented in a head to tail fashion to generate farnesyl
pyrophosphate. The enzymes that are responsible for the synthesis of E,E-farnesol from farnesyl
pyrophosphate are a Mg -independent phosphatidate phosphatase and diacylglycerol
+2

pyrophosphate phosphatase. These enzymes are encoded by the gene Lpp1p and Dpp1p
respectively in Saccaromyces cereviseae and by the genes Dpp2 and Dpp3 in Candida (Toke, et
al., 1998). Assays to determine the activity of these enzymes were based on cytosolic extracts
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where farnesyl pyrophosphate was added as a substrate and the amount of farnesol created was
measured.
Farnesol is characterized as a head-to-tail linear sesquiterpene. Isoprenoid compounds
have been identified in plants and fungi that yield distinctive odors and flavors. For example,
farnesol yields the characteristic odor of Channel No.5 and the original source of purified
farnesol was from C. albicans (Hornby, et al., 2001). E,E-farnesol has also been isolated from
the anal scent glands of Nutria, a rodent that is an invasive species in the wetlands of Louisiana.
Nutria use scent to establish territory and attract mates. E,E-farnesol is thought to be a useful
bait compound to improve the efficiency of traps (Lee, et al., 2007). E,E,-farnesol is also a
major constituent of secretions from the temporal gland of male Asian and African Elephants.
These scent glands are located on the face lateral to the eye. When male elephants are preparing
to become aggressive the secretions of the temporal gland increase and the substance is rubbed
on trees to indicate to other males territorial boundaries and to attract potential mates. E,Efarnesol has also been isolated from the Nasonov gland of honeybees. This secretion is used to
indicate sources of food sources to nestmates (Granero, A.M. et al., 2005).
The fate of farnesyl pyrophosphate, if it is not converted into farnesol, is to form subunits
for cell membrane material generated in the lipid synthesis pathway. The mode of action of a
majority of anti-fungal chemotherapeutic agents that have been effectively used against C.
albicans target the enzymes of the lipid biosynthetic pathway that are responsible for
synthesizing lanosterol, Zymosterol, and Ergosterol (Carrillo-Munoz, et al., 2006). The
blockages of these enzymes lead to an increase in membrane permeability and an increase in
farnesol production. As a result, invasive C. albicans is no longer able to maintain intracellular
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concentration gradients of potassium and other important ions and osmotic pressure leads to lysis
of the cell. It is the goal of most anti-Candidal drugs to target the lipid pathway and results in a
reduction of cell wall integrity. A second effect of the disruption of the lipid biosynthetic
pathway is the increase in the production of farnesol. Increased farnesol production causes
newly forming cells to remain as yeast and do not readily enter the hyphal form.
E,E- farnesol is synthesized in virtually all eukaryotic cells ranging from fungi to humans.
The general interest here is farnesol that is synthesized by the opportunistic fungal pathogen C.
albicans. It has been demonstrated that farnesol is released continuously from the cell in the
amount of approximately 0.13mg/g (dry weight) by the two C. albicans strains A72 and CAI-4
(laboratory strains) (Hornby, et al., 2004). It also has quorum sensing capabilities (Hornby, et
al., 2001) that have a significant impact on biofilm development and architecture. When levels
of farnesol reach a threshold level the ability of the fungus to transition from a yeast form cell
into a hyphal form cell is inhibited. This morphological shift, defined as dimorphism, is a
significant virulence factor for C. albicans infections. When this organism is in the hyphal state,
biofilm formation is robust and tissue invasion is possible.
The ability of farnesol to inhibit the hyphal state and lead to more yeast-form cells to
develop results in a less robust biofilm and reduced tissue invasion. This inhibition occurs at the
genetic level where there is a repressor that is activated that leads to the blockage of transcription
factors that lead to the synthesis of genes responsible for triggering hyphal differentiation. It has
been shown that, in a developing biofilm, cells that have already committed to the hyphal state
are resistant to the effects of farnesol. Only newly developing cells will be susceptible to the
hyphal-inhibiting effects of farnesol (Mosel, et al., 2005; Ramage, et al., 2002) In general,
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morphological transition from the yeast to hyphal form is triggered by increased concentrations
of carbon dioxide, increased temperature, alkaline pH, serum, or the presence of Nacetylglucosamine (Hornby, et al., 2004). It has been shown that three independent signal
transduction pathways mediate the transition into the hyphal state. Each pathway depends on
specific environmental triggers. It has been shown that farnesol is able to inhibit all three of
these pathways. It is still unclear if the inhibition is general or specific for each trigger.
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Figure 5: Molecular regulatory pathways to control dimorphism in C. albicans

Figure 5:

The importance of farnesol in the microbial world is becoming increasingly apparent. It
has been demonstrated that farnesol is instrumental in controlling dimorphism in the fungus
Candida albicans. E,E-farnesol has also been shown to aid C. albicans in competition with other
fungal species that may attempt to occupy the same niche. In a study with Aspergillus nidulans
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it was shown that E,E-farnesol induced apoptosis (Seminghini, et al., 2006). It was also shown
that E,E-farnesol protected C. albicans from attack by reactive oxygen species (Westwater, et al.,
2005). Preliminary 2D DIGE results indicate that farnesol secreted by C. albicans influences the
expression of virulence factors in P. aeruginosa and alters quorum sensing systems by
suppressing homoserine lactone production and increasing PQS quorum sensing. The strains P.
aeruginosa PAO1 and C. albicans SC5314 were chosen for use in this study because their
genomes have been completely sequenced and annotated.

Quorum sensing disruption in nature and the potential use in the clinic

Traditional antibiotics that inhibit the ability of bacteria to grow within the human body has
historically been an effective strategy in preventing infectious disease. However, the emergence
of resistant organisms has caused treatable diseases to become a more formidable challenge to
the medical community. The extreme pressure that growth-suppressing drugs has on bacteria has
an equally strong ability to create resistance through active selection, thus increasing the
incidence of resistance. The development of an anti-pathogenic drug is an emerging area that is
based on knowledge of the regulation of virulence factors by quorum sensing mechanisms.
According to the anti-pathogenic drug principle drugs that target quorum sensing systems will
prevent the ability of bacteria to adapt to the human environment and block virulence and
pathogenic traits (Hentzer, et al., 2003). Quroum sensing virulence factors in P. aeruginosa
include the secreted compounds elastase, alkaline protease, rhamnolipids, phenazines, cyanide,
lectins, and chitinases. The response of the immune system, when challenged with quorum
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sensing deficient mutants of P. aeruginosa, has been shown to be faster overall exhibiting
increased strength of oxidative bursts from PMN and faster accumulation of antibodies
(Givskov, et al., 2006). Virulence studies with C. elegans and quorum sensing deficient mutants
of P. aeruginosa have also demonstrated increased rates of survival in the animals challenged
with the mutant strains. The mechanisms used to kill the animals are quorum sensing regulated
compounds.
Potential targets for anti-pathogenicity drugs involve three components of the quorum
sensing system: the signal generator, the signal molecule, and the signal receptor. In nature, the
use of quourum sensing disruptors has been found to be an effective strategy to prevent infection
and competitive advantage. A plant infected with the tissue degrading plant pathogen E.
carotovora will increase the pH surrounding the wound site. The alkaline pH causes the lactone
ring of AHL to open and degrades the signal. The end result of the blockade of quorum sensing
signal is the reduction in tissue damage (Byers, et al., 2002). The marine alga Laminaria
digitata produces and secretes hypochlorous and hypobromous acids. These compounds are
used industrially to prevent biofouling, act as the active sanitizer in swimming pool products, and
are generated by activated neutrophils. These compounds react with oxidized acyl-homoserine
lactones and provide a competitive advantage to the alga. There are enzymes that degrade AHL
by catalyzing lactonolysis and reduce the concentration of active AHL. These enzymes, called
AiiA, have been isolated from Bacillus species. Homologues of these enzymes have also been
found in Agrobacterium tumefaciens, Arthrobacter sp., Klebsiella pneumoniae, Comamonas sp.,
and Rhodococcus sp (Givskov, et al., 2006).
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The development and maintenance of the biofilm and the induction of most virulence
factors are both under the control of quourm sensing regulated genes in some organisms such as
P. aeruginosa. Quorum sensing mutants have been shown to be deficient in biofilm formation
and the establishment of a robust infection. A growing area of research to develop novel ways to
prevent infection by pathogenic microorganisms is to take advantage of quorum- sensing systems
and the potential disruption of these systems (Bjarnsholt, 2007).
A drawback in the further development of this form of therapeutic is the uncertainty in
establishing protocols for clinical trials and gaining FDA approval. There is concern about
denying patients in clinical trials antibiotics with infectious disease in order to test the efficacy of
quorum-sensing inhibitor drugs. The pharmaceutical industry, scientists, and government
regulators are at a critical cross-roads that could decide the fate of this form of treatment for
infectious disease (ASM Cell-Cell Communication in Bacteria meeting, Austin TX Oct. 7-10
2007). The science behind this developing area of therapy for infectious disease is based on
stemming the lines of communication among pathogens to derail the pathogenic process and
dampen the virulence of the invading pathogen.
With the use of quorum sensing disruptors it may be possible to prevent the formation of
biofilms on biotic and abiotic surfaces or to prevent the production of toxins and virulence
factors that are quourm-sensing regulated. A major focus of this study was to look at the ability
of a cell-signaling compound produced by C. albicans, E,E-farnesol to interfere with the
quorum- sensing ability of P. aeruginosa.
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Objectives of this work
The goal of this study was to identify proteins that are differentially expressed under
different growth conditions in P. aeruginosa when exposed to E,E-farnesol or whole cells of C.
albicans. 2D DIGE® based proteomics was used to explore the effects that varying doses of E,Efarnesol had on planktonic P. aeruginosa strains PAO1 and GSU3. Several proteins of interest
were identified in this study that can be grouped into the categories Membrane-associated,
Motility associated, Metabolism associated, and Stress associated. Subsequent studies that were
based on 2D SDS PAGE proteomics found proteins that grouped within the same categories as in
the DIGE® based study. These studies altered the growth conditions and method of exposure to
elements of C. albicans. This project provided a launch-point to design further studies to dissect
the intricacies of the relationship between P. aeruginosa and C. albicans.
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Materials and Methods

Strains and Cultivation
The strains of P. aeruginosa used were PAO1 and GSU3 obtained from 50 % glycerol
stocks maintained at Georgia State University. P. aeruginosa PAO1 is a sequenced laboratory
strain and P. aeruginosa GSU3 is a clinical isolate from a case of bilateral keratitis that was
identified and named at Georgia State University. The strain of C. albicans used was SC5314
and is a sequenced strain that was obtained from ATCC. All strains were maintained in 1 ml
aliquots of 50 % glycerol: standardized cell suspension at -80°C in cryovials (Nalgene catalog
no. EF6835A). The cell suspension stocks were made in order to insure fresh cultures for each
experiment. In order to revive the cells for use, the cryovial was defrosted at room temperature
and then mixed by vortexing until the cells were evenly suspended. Then 100 µl of the stock was
added to 10 ml of sterile LB- Miller medium in a sterile 15 ml Falcon tube and vortexed to mix
thoroughly. The cells were first grown on LB-Miller agar (15% w/v). The plates were
inoculated with a 10 µl disposable loop using the quadrant streak technique and incubated
overnight at 37°C. The volume of working liquid culture depended on the total volume of the
flask. Typically, a 250 ml baffled flask was used with 100 ml of fresh sterile LB-Miller broth.
Two to three isolated colonies from the LB-Miller plate were used as inoculum to start the
working liquid flask cultures. These liquid cultures were grown at 37°C and shaking at 130 RPM
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in an Innova 4080 (New Brunswick Scientific) environmental rotary shaker. After growth for 16
hours the optical density was recorded (absorbance at 600 nm) and this was used to inoculate
experimental conditions with a known density of cells. The flasks employed in the farnesol
experiments were 50 ml flasks containing 10 ml of pre-warmed (to 37°C) LB-Miller broth.
These flasks were shaken in the environmental shaker at 300 RPM.
Growth Phase: Growth phase was determined by measuring OD600 of 1 ml samples using
the Turner spectrophotometer (model SP-830). The growth phase in the farnesol experiments
were based on values provide by [personal communication] Dr. Jayne Robinson at the University
of Dayton (Dayton, Ohio) to determine mid-logarithmic growth. The starting OD600 was 0.05
and the ending OD600 was 0.7. The optical density was adjusted as required by adjusting the
volume of culture added to fresh media.
Preparation of farnesol: E,E-farnesol was stored at -20°C until need. Once the bottle was
opened, the bottle was flushed with nitrogen to purge any air /oxygen. Due to the hydrophobic
nature of E,E-farnesol it was necessary to add methanol to increase its solubility. The 3.8 M
stock of E,E-farnesol was diluted into 100% methanol according to the concentration needed in
each experiment. (In the experiments reported here, 25 µM and 250 µM concentration of E,Efarnesol were utilized). The following volumes were based on the total volume of media used in
the experiment. A 38 mM stock was made by adding 10 µl of the 3.8 M straight from the bottle
into 990 µl of methanol. Then 66 µl of this was added to 10 ml of the culture media to yield a
final volume of 25 µM. In the 250 µM experiment, 100 µl of stock E,E-farnesol was added to
900 µl of methanol. Then 66 µl of this solution was added to 10 ml of culture media. It was
important to note that the final volume of the E,E-farnesol: methanol ratio was the same although
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the concentration was different. DMSO was also used to solubilize E,E-farnesol and was used in
the same proportions as described in the previous section with methanol. DMSO was used for
the biofilm experiment and the antibiotic susceptibility experiment.
Cell cultivation and harvest
The appropriate cell stock were removed from glycerol stocks and grown overnight on agar
plates (see previous section on strains and cultivation). Isolated colonies were then selected with
a disposable loop and added to 250 ml flasks containing 100 ml of fresh pre-warmed (37°C) LBMiller media and shaken overnight at 130 RPM. The optical density was recorded and the
volume of culture necessary to inoculate a culture of 0.05 OD600 was then added to six 50 ml
flasks containing 10 ml of fresh pre-warmed LB-Miller. The cultures were incubated until they
reached an OD600 of 0.7 at 37°C and 300 RPM. The appropriate volume of cell suspension from
the first set of six 50 ml flasks was then added to a second set of six flasks containing either 25
µM or 250 µM of E,E-farnesol in 10 ml of pre-warmed LB broth, and these flasks were
incubated at 37°C and 300 RPM. These cultures were allowed to grow until they reached an
OD600 of 0.7.
Once the cells reached the appropriate OD600 (approximately 6 hours following
inoculation) they were transferred into sterile 15 ml conical tubes (Falcon®) and placed on ice.
Once chilled, the samples were placed into a tabletop centrifuge (Beckman Coulter Allegra 64R
Centrifuge, Fullerton, CA.) that was cooled to 4°C. The cell suspension was spun at 10,000 x
rpm for 10 minutes. The supernatant was removed and the cells were washed in a wash buffer
appropriate for proteomics (see appendix for magnesium based wash buffer). This cycle was
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repeated three times. At the end of the third centrifugation, the supernatant was removed and the
cell pellet was resuspended in 1 ml of wash buffer and transferred into a sterile 1.5 ml
Eppendorf® tube. The cells were again centrifuged at 10,000 X G for 10 minutes in an
Eppendorf Microfuge® unit. Then the supernatant was removed and the cell pellet was flash
frozen in an acetone and dry ice bath and placed in the -80°C freezer until disruption. The packed
cell weight of each pellet was recorded to insure thorough disruption.
Cell Disruption
The packed cell pellet was removed from the -80°C freezer and allowed to thaw at room
temperature. Once the pellet began to thaw, the appropriate lysis buffer for proteomics (see
appendix) was added to the pellet with a sterile pipette tip. The pellet was vortexed to disperse it
into the lysis buffer. If the pellet was difficult to disperse, a pipette was used to aspirate the
liquid until the cell pellet was not longer visible. Once the pellet was dispersed, the entire
contents were transferred to a sterile, 15 ml conical tube (Falcon®) and placed on ice. Once the
liquid was chilled, the Falcon® tube was placed under the sonicator tip. The tip of the sonicator
was placed in the center of the liquid as closely as possible in all directions. It is important to
note that the tip was not too close to the surface as foaming would occur. The level of the tip
was as close to the center of the total volume as possible with careful attention paid that the tip
does not touch the walls of the tube. The Falcon® tube was then placed in a beaker of ice water
on top of a stir plate. A stir bar in the bottom of the beaker allowed for the ice water to stir and
most effectively remove heat from the cell lysate.
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Figure 6: Schematic diagram for set-up of microtip sonication of packed cell pellet of P.
aeruginosa

Sonicator tip

Falcon® tube

sample

Beaker with ice

Stir bar
Stir plate
Figure 6: Diagram depicting the setup for protein pellet lysis by micro-tip sonication.
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Sonication was used to disrupt the cell membrane and liberate the protein containing cytosol.
The sonicator used was the Misonix Sonicator Ultrasonic Processor XL 2020. The microtip was
a 1.5 cm tip and the maximum power level reached was 3. The cycle used was a total run of
three minutes with one-second power on and 0.5 seconds power off. The optimum power for
sonication was reached when the liquid visibly cavitated around the microtip when the peak
power was reached during the pulse. The pitch was very important for this step also; the sound
was not sharp, it was a smooth grinding sound. Early indications that air was getting into the
liquid was a “sucking” sound if this did occur the power should be reduced to prevent foaming.
In the event that foaming did occur, the Falcon® tube was removed from the sonicator tip and
placed in a centrifuge and spun at a low speed for less than five minutes to get the foam out.
Then the sample was recorded in the lab notebook and then sonication completed. Once
sonication was complete, the lysate was transferred to a lo-bind® Eppendorf tube and centrifuged
at 10,000 x g to sediment any cell membrane materials or whole cells. Then the protein
containing lysate was removed and aliquoted into 50 to 100 µl fractions. Once labeled and
aliquoted, the lysate was stored in the -80°C freezer until ready for use.
The same procedure was used to disrupt the membrane for C. albicans with the exception
that the time for sonication was extended to 20 minutes and glass beads (approximately 200 mg
per cell pellet) (Sigma G1277- acid washed) was added. During the sonication optimization
process the lysate was sampled periodically throughout the soncation and centrifuged to
determine if cells were lysing properly and efficiently. A quick and easy way used to determine
if cells were lysed properly is that the color of the supernatant following centrifugation appears
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amber in color. If the supernatant appeared clear then more sonication was necessary.
Protein Quantification
To quantify protein present in the sonicated lysate, a frozen sample was removed from the
-80°C freezer, and allowed to thaw at room temperature. Once defrosted, the supernatant was
ready for quantification. Quantification was a critical step in the proteomics workflow and a
great deal of attention was paid to accurately quantitate all samples (biological replicates) to be
studied. The lysis buffer used for proteomics presents some challenges in quantification so a
modified Lowry protein quantification kit was used (2D Quant Kit- GE Healthcare Piscataway,
NJ.)
Protein assay for 2D proteomics
Traditional protein assays such as the Bradford based assays utilize Coomassie Brilliant
blue binding by the protein. The CHAPS present in the lysis buffer will also bind to the
Coomassie and provide an inaccurate result. The traditional Lowry assay, which relies on the
reduction of cupric ions to cuprous ions, cannot be used due to dithiothreitol (DTT) and thiourea
present in the lysis buffer that will form complexes with the cupric ions and provide inaccurate
results. The modified Lowry assay takes advantage of the binding of cupric ions that bind to the
polypeptide backbone following precipitation and resuspension in an appropriate alkaline buffer.
Once the ions have bound to the protein in the sample, a colorimetric agent is used that binds to
unbound cupric ions. This assay creates an inverse relationship between the degree of color
change and the concentration of protein present. This assay employs a 0-50 µg BSA standard
curve and is linear in the range of zero to 50 µg of protein and the volume range of one to 50 µl
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of sample can be used. It is important to test multiple volumes of sample in order to most
accurately quantify the amount of protein present in the sample lysate. It is important to perform
the standard curve at the same time and every time a sample lysate is quantified. Environmental
conditions in the room can affect the optical densities, thus the most accurate standard curve
should reflect the conditions in the lab at the exact time the sample is also quantified. Once the
standard curve is completed, the curve should be entered into an Excel® spreadsheet (Microsoft,
Seattle Wa.) and a regression line should be placed on the graph. The equation for the regression
line is then used to determine how much protein is present in the sample. The optical density of
the sample is placed in the y value. The total volume of the sample assayed was divided by x
(the protein concentration in µg/µl) to give the total amount of protein present in the sample in
units of µg/µl. It is imperative that a minimum concentration of 5 µg/µl be used in order to have
a sufficient quantity of sample for labeling with CyDyes® and identification by massspectrometry. If this protein quantity is not met it is necessary to revisit the disruption method
used and possibly consider concentration of the sample lysate prior to quantification.
CyDye® labeling
The goal of this stage is to label each sample with a CyDye® fluor and create the pool of
samples that will act as the internal standard. Several steps are necessary in this stage. The first
is the randomization of the samples. This can be accomplished by drawing a circle that has
smaller circles that make up its circumference. There should be one smaller circle for each
sample in the experiment. A sample label for each sample should be placed in the small circles
randomly. The next step is to pair each of the small circles randomly. Drawing an arrow is
useful. The base of the arrow can act as the Cy3 labeled sample and the point of the arrow can
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act as the Cy5 labeled sample. It is important that each sample have one Cy3 and one Cy5
pairing.
Figure 7: Diagram sample for randomization of CyDye® labels

Figure 7: Schematic diagram for method of randomization of samples to organize CyDye® labeling and pairing on
2D SDS PAGE gels. Concept adapted from Tracy Ashcroft from the University of Georgia Core Proteomics Facility
Athens, GA.
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The next step is to create a table for which samples will be on which gel and what dye will be
used. Once again it is important that each of these samples are labeled with both dyes and they
are randomly paired on each gel.

Table 2: Matrix of pairing of samples for randomization
Samples

Gel 1

Control 1

Cy3

Control 2

Gel 2

Test 2
Test 3

Gel 4

Gel 5

Gel 6

Cy5
Cy3

Control 3
Test 1

Gel 3

Cy5
Cy3

Cy5

Cy5

Cy3
Cy5

Cy3
Cy5

Cy3

Table 2: Method to graphically represent cross-labeling and randomization of all samples for a robust 2D DIGE
based study.
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The next step is to determine how much protein is available for labeling and how much total
protein will be loaded onto each gel. The more concentrated the CyDyes® used to label the
samples the more signal the low abundance proteins will receive. The suggested range is
between 200 and 1000 pM CyDye®/ µg of protein. The most limiting factor in determining how
much total protein to load onto the gel is your least concentrated sample. This least concentrated
sample will determine the maximum amount of protein that is available for the three gels that
must be present. There are two analytical gels and one preparative gel. It is important that a
sufficient amount of protein is present on the preparative gel so that each spot, even the low
abundance ones, have enough protein present to be identified positively by mass-spectral
analysis.
The labeling process itself is not difficult but great attention must be paid to accurate
pipetting. It is important that the samples are kept on ice and in the dark. Each of the samples is
labeled individually in their own lo-bind® Eppendorf tube. However, the standard should be
created at this step by combining equal concentrations of each sample that will be present in the
study. This pooled sample will contain all replicates and the control and experimental samples in
one lo-bind tube and will be labeled at the same time. The protocol should be closely adhered to
in order to ensure that appropriate labeling has occurred. Once labeling is complete, the Cy3,
Cy5, and Cy2 samples are combined according to the randomized scheme designed above.
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Figure 8: Workflow for CyDye®labeling

Figure 8: Depiction of workflow scheme to label samples and combine into one single gel. Source: GE HealthcareProteomics revision 3, 2006.
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First dimension isoelectric focusing (IEF)
Isoelectric Focusing (IEF) is based on the separation of proteins according to pI. This
value is determined by the net electronegativity of the side chain of each amino acid in a peptide
chain. As the pH of a peptide increases so to does its pI. Strip gels are utilized that have a preformed immobilized pH gradient and when sample is added to the strip and with an electric
current, the peptides will migrate until they reach a neutral point this neutral point coincides with
that peptide’s pI. The graph below depicts how the protein’s pH coincides with the pI (Figure 9).
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Figure 9: Isoelectric Point of Peptides

Figure 9: Graphical depiction of pH where peptides reach their respective pI, or the isoelectric point where no
electrical force is able to cause movement of the peptide. Graph generated by Shelby L. Jones-Dozier adapted from
2-D Electrophoresis: Principles and Methods (GE Healthcare, Piscataway NJ)

This technique is useful in a 2D SDS PAGE because it allows for separation of peptides on a
physical property distinctly from the different peptide’s molecular weight. The presence of
CyDyes® does not significantly change the pH of a peptide so it is possible to label the protein
prior to any separation.
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This step is very sensitive to salts, contaminants, and detergents that may be present in the
sample lysate. The first step in Isoelectric focusing (IEF) is to rehydrate the first dimension
strips. The first dimension strips are rehydrated in a buffer that contains IPG ampholites
appropriate for the strip pI. The rehydration buffer also contains urea and thiourea to keep the
proteins in solution. It is important to note that the urea is present at 8 M. In order to prevent
crystallization, it is important to keep the strips out of contact with the air. This is accomplished
with the application of the mineral-oil based DryStrip® cover fluid. There are several options in
IEF concerning how the sample is applied. Typically, analytical gels utilize the cup-loading
method to introduce the proteins into the gel following strip rehydration. Preparative gels
typically utilize in-gel rehydration in order to load more protein in to the gel itself. The cuploading method produces fewer streaks, in highly abundant proteins, and allows for better
resolution of low-abundant spots that may be near high abundant proteins. The in-gel
rehydration method is used for preparative gels because the higher protein loads that are
necessary for a preparative gel can clog the cup.
The protein samples were first reduced with dithiothreitol (DTT) containing solubilization
buffer at 4°C for 30 minutes. The samples were then combined with the appropriate amount of
Destreak® solution (GE Healthcare, Piscataway NJ.) for each strip. The samples were added to
each well for each dried strip. The strips were applied to the well face down so that the protein
samples could be absorbed into the gel as it reswelled. The strips were then covered with
DryStrip® Cover Fluid (GE Healthcare, Piscataway, NJ) and allowed to sit for approximately 24
hours at room temperature. Once the samples had been adsorbed into the gel, the gel strips were
placed into the ceramic gel-boats. The strips were placed face up so that the wicks and
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electrodes came into direct contact with the gel surface. The amount of current applied depends
on the length of the strip and the pI range of the strip. In this study, 24-cm strips were used and
the amount of power applied was altered depending on the pI range of the strip.
Table 3: Isoelectric focusing protocol for a 24 centimeter Imoboline® pH 3-11 range strip,
at 50 µA per strip
Step Voltage mode

Voltage

Time (h:min)

Step and Hold

500

1:00

Gradient

1000

8:00

Gradient

8000

3:00

Step and Hold

8000

3:45

Table 3: Protocol adapted from GE Healthcare Handbook for 2D Electrophoresis, revision 2007.
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Table 4: Isoelectric focusing protocol for a 24 centimeter Imoboline® pH 4.5-5.5 range strip,
at 50 µA per strip
Step Voltage mode

Voltage

Time (h:min)

Step and Hold

500

2:00

Gradient

1000

5:00

Gradient

8000

3:00

Step and Hold

8000

10:30

Table 4: Protocol adapted from GE Healthcare Handbook for 2D Electrophoresis, revision 2007.

Following IEF, the gel strips were individually placed into equilibration tubes, wrapped in foil to
protect from light, and stored at -80°C until ready for use.
Equilibration of IEF gel strips
Two solutions are made in order to equilibrate the 1D strips following IEF and prior to SDS
PAGE at room temperature. The strips are first exposed to 0.5% DTT for 15 minutes with
shaking. The strips are laid on their side on a shaker at 85 RPM. The speed should be adjusted
so that the solution fully covers the strip. The DTT solution is then discarded and placed into
hazardous waste containers and the strips are then covered with a 4.5% iodoacetamide solution
and incubated for 15 minutes at 85 RPM at room temperature. The strips are then washed with
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1X SDS electrophoresis buffer and attached to the surface of the SDS PAGE gel with agarose gel
(see appendix). The IEF gel is placed on the top of the SDS PAGE gel so that no bubbles are
present. The agarose is then allowed to solidify before the gels are placed into the
electrophoresis tank.
Second dimension SDS PAGE
Second dimension sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS PAGE) is
based on the separation of proteins by their molecular weight. This is a commonly used
technique to separate proteins and when coupled with IEF can be a highly robust tool to separate
a high quantity of proteins from a sample. The degree of resolution in SDS PAGE can be
controlled by the percentage of acrylamide in the gel. For this study, a 1-mm thickness gel was
used with a single percentage of 12% that is effective for separating proteins in the molecular
weight range of 14- 200 kilo-daltons (KDa).
Casting SDS PAGE gels
The gels were prepared in the lab for each run. The protocol for plate washing was critical to
ensure that mass-spec analysis was not contaminated with keratin, dust, or residue from other
studies. The plates were first scraped with a plastic Wonder-Wedge® tool to remove any residual
gel. The plates were then soaked for no more than 6 hours in Contrad 70 (Decon labs catalog no.
1003) detergent. The plates were then scrubbed with a soft plastic scrubber sponge to ensure any
material and debris is removed. The plates are then rinsed with deionized water, washed with
Decon® a second time, rinsed with deionized water and rinsed a final time with double-deionized
water. The plates are then soaked in 1 % Hydrochloric acid for 2 hours at 25 RPM on a shaker
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Innova Platform Shaker (New Brunswick). The plates are then rinsed again with deionized
water and double-deionized water. The plates are then allowed to dry on the Ettan® plate holders
and covered to protect from dust as the gels air dry. The face of the plate that is to be used to
attach the gel to should be determined. It is possible to attach the gel to the top plate or the
bottom plate (with spacers). However, consideration must be made at the time of scanning to
ensure that the robotic picker picks the proper region of the plate. The gel face that the gel is
adhered to is placed on a Lab-Soaker face up and is covered with 4 ml of Bind-Silane® solution
(see appendix). The solution is spread with a dust-free KimTech® Crew Pure CL4 wipes
(Kimberly Clark, 7605) and allowed to air dry. The solution is allowed to cure for one hour then
the reference markers are placed on the plate. They should be approximately 10.5 cm from the
bottom of the plate and 1.5 cm from the outside edge of the plate. The plate is allowed to sit for
an additional hour before use. The acrylamide gel solution was prepared and allowed to de-gas
for 10 minutes before use. The gel solution was prepared in a vessel that has a pour spout or a
bottle with an easy pour ring. Once the plates have cured for two hours they are wiped with 200
proof ethanol with a crew wipe and allowed to sit for 10 minutes to allow complete removal of
all volatile components. The gel sandwiches were then assembled in the gel caster. The
assembly protocol for the Ettan Dalt® six or the twelve gel caster is the same. First a thin plastic
spacer is placed at the back of the caster unit. Then a back plate is placed and firmly pushed to
the bottom left hand corner. Then the top plate is placed and firmly pushed to the bottom left
hand corner and the wonder wedge is used to ensure that the plates are as far as they can go to
the bottom left. Then a second thin plastic spacer is put on top of the top plate. This process is
repeated until all six or twelve gel sandwiches are assembled. The thick plastic spacers were
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then used to fill in the remaining space to ensure a tight fit once the cover plate for the caster was
put into place. The gel solution was then poured slowly into the gel caster to ensure that no
excess bubbles were formed. The gel solution was poured until the top level was 1 cm above the
desired level of the gel. Then 1 ml of water saturated butanol solution (see appendix) was placed
on top of each gel with a 1 ml pipette. The pipette tip was run along the entire length while the
butanol solution was slowly released in even volumes. The gel caster was then covered with a
piece of cellophane until the gels solidified. This took approximately two hours. The gels were
then removed from the caster, inspected for defect, and the butanol solution on top of the gel was
washed off with double-deionized water and then placed on its side in the gel rack to allow all of
the water to drain from the top of the gel. Then the gels were covered in gel-storage solution
(see appendix) taking special care to cover the top of the gel where the IEF gel will seat). The
gels were laid horizontally at room temperature to allow complete polymerization to occur. Prior
to running the second dimension the top of the gels was washed again to remove any residual gel
storage solution and allowed to sit on its side in the gel storage rack. The power used for most
gel runs was based on an overnight run where 1.5 watts per gel was applied with the Ettan Dalt®
six or twelve system. A 2X electrophoresis buffer (see appendix) was used in the upper cathodic
buffer chamber and a 1X electrophoresis buffer (see appendix) was used in the lower anodic
buffer chamber.
After the gel run was complete the gels were prepared according to the dyes used for
imaging. If the CyDyes® were used, the gels were washed with water to remove any excess
electrophoresis buffer and placed into a light-protected box with water and transported
immediately to the Typhoon® Variable-Mode Imager 4900 for imaging. In the event that a
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saturation dye was used, the top plate was carefully removed from the gel sandwich and the gels
were placed into individual containers with fixing solution (see appendix) and allowed to sit for
2-24 hours at 4°C. The protocol for each saturation stain should be followed. Post-staining of
CyDye® gels also followed the saturation stain protocol.
Imaging and analysis
Gels were imaged with the Typhoon Variable Mode Imager model no. 4900. ImageQuant®
(Molecular Dynamics, version 5) was used to view the gel images. This software was used to
crop the gel images and convert them to the correct electronic format for the downstream
analysis software. Gels that were stained with CyDyes® were analyzed using DeCyder® version
10. Gels that were saturation stained with Coomassie, Deep Purple®, or silver were analyzed
using ImageMaster Platinum version 6. Both of these software programs follow the same
guidelines to generate a list of significant proteins.
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Figure 10: Overview of approach to identify proteins of interest in DeCyder® version 6.5
and ImageMaster Platinum version 6

Spots are matched between
the same samples to create
two groups to be compared
for biological differences

Proteins of interest identified

Figure 10: Graphical depiction of workflow for the detection of proteins of interest in 2D DIGE projects.
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Spot excision
A pick-list is generated within the analysis software that creates a text (.txt) file that is moved to
the computer that operates the Ettan Dalt® Spot Picker (GE Healthcare, Piscataway NJ) that is
depicted below in Figure 10.

Figure 11: Ettan Dalt® Spot Picker

Figure 11: Image obtained from GE Healthcare product catalog 2008

After the text file is imported into the Spot Picker control software, the location of the reference
markers, the thickness of the gel, and the location of the microtiter plate that will hold the gel
plug are determined. Once these parameters were set, the program was initiated and the protein
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spots were excised. Stains that were visible with the naked eye were inspected to ensure that the
desired spots were excised. Stains that emitted only a fluorescent signal were imaged again with
the Typhoon imager to ensure that the correct spots were excised. After this was verified, the
protocol to proteolytically degrade the peptides and extract them from the gel was initiated.
Protein digestion (Trypsinization)
Proteins immobilized within the acrylamide gel matrix are exposed to trypsin that causes
proteolytic degradation. Trypsin is a serine protease that degrades peptides at the carboxyl side
chains of the amino acids lysine and arginine. Porcine trypsin from Promega was used in this
study. The sample gel plugs are exposed to 100 µl of a 50 mM ammonium bicarbonate/ 50%
acetonitrile solution for 20 minutes at room temperature. The solution is then removed by
careful pipetting so as not to disturb the gel plug then fresh 50 mM ammonium bicarbonate/ 50%
acetonitrile is allowed to sit for an additional 20 minutes. The 50 mM ammonium bicarbonate/
50% acetonitrile is again carefully removed by pipetting then replaced with 75% acetonitrile.
The 96-well plate is then placed in the Eppendorf Vacufuge® (Model no. 22331 Hamburg,
Germany) unit for 30 minutes with no heat. The dried and dehydrated gel plugs were then
exposed to approximately 7 µl of a 20 µg/ ml solution of trypsin. Sufficient volume of the
trypsin solution is added to cover the entire gel plug. The trypsin is kept at 4°C until added to
the gel plug. The 96- well plate was placed on ice for 30 minutes once the trypsin was added to
allow the trypsin to become adsorbed into the gel before proteolytic digestion began. After 30
minutes, the plate was wrapped thoroughly with Parafilm to prevent drying prior to placing into
the 37°C incubator overnight. Following the overnight incubation, 100 µl of a 50% acetonitrile/
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0.1% trifluoroacetic acid (TFA) solution is added to the gel plug in order to extract the peptides
from the gel matrix. The extraction solution was added in two fractions. First 60 µl of the 50%
acetonitrile/ 0.1% TFA solution was added to the gel plug and allowed to sit for 20 minutes at
room temperature. Then the solution was removed by pipette and placed into a fresh Lo-Bind
Eppendorf® tube and 40 µl of the 50% acetonitrile/ 0.1% TFA was added to the gel plug. This
solution was allowed to sit for 20 minutes at room temperature. Following incubation, the 40 µl
was combined in the same Eppendorf ®tube with the original 60 µl that was removed in the first
set. The Eppendorf ®tubes were then placed in the Eppendorf Vacufuge® for 2 hours or until the
liquid was completely evaporated. The samples were then stored at -20°C until ready for use.
The maximum storage time is one week.
Zip-Tipping® and MALDI TOF-TOF
Samples were removed from the -20°C and allowed to come up to room temperature for 5
minutes. Then 1.5 µl of neat formic acid was pipetted into each sample tube and vortexed
briefly. Then 8.5 µl of 0.1% trifluoracetic acid (TFA) was pipetted into each sample tube and
the sample was vortexed at low speed for five minutes at room temperature. The samples were
then centrifuged briefly to bring all of the liquid down into the bottom of the Eppendorf® tube.
The Zip-Tip® (Millipore) was then prepared by first wetting and then aspirating with 0.1% TFA.
The sample was then bound to the C-18 column and washed with 0.1% TFA. The sample was
released from the column with the elution solution and spotted onto the MALDI plate. Once the
sample dried, the alpha-cyano-4-hydroxycinnamic acid matrix was applied (Agilent
Technologies, catalog no. G2037A). The MALDI plate was then placed at 4°C until ready for
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analysis. The samples were analyzed at the Emory Microchemical Facility, Atlanta GA.
Proteomics experimental set-up
Overview: Each experiment varied in the experimental treatment with farnesol. The growth of
working cultures, downstream harvest, and preparation for 2D proteomics followed the methods
described in the previous sections.
Experiment 1: P. aeruginosa PAO1 exposed to 30 µM racemic farnesol, IPG range 3-11
The protocol to initiate this experiment followed the procedure introduced in the cell
cultivation and harvest section found earlier in the Materials and Methods section. The
concentration of the farnesol stock solution was altered so that 66 µl of racemic farnesol at a
final concentration of 30 µM was added to the culture media.
Experiment 2: P. aeruginosa PAO1 and GSU3 exposed to 25 µM and 250 µM E,E-farnesol, IPG
range 3-11
The protocol to initiate this experiment followed the procedure introduced in the cell
cultivation and harvest section found earlier in the Materials and Methods section. The
concentration of the farnesol stock solution was made exactly as indicated in this section so that
only 66 µl of farnesol and methanol was added. The concentration of the stock solution varied
so that the final concentration was either 25 µM or 250 µM in the culture media.
Experiment 3: P. aeruginosa PAO1 exposed to 25 µM E,E-farnesol, IPG range 4.5-5.5
The protocol to initiate this experiment followed the procedure introduced in the cell
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cultivation and harvest section found earlier in the Materials and Methods section. The
concentration of the farnesol stock solution was made exactly as indicated in this section so that
only 66 µl of farnesol and methanol was added and the final concentration of farnesol was 25
µM.
Experiment 4: P. aeruginosa PAO1 catheter lumen biofilm exposed to 250 µM E,E-farnesol,
IPG range 3-7
The initial cultivation of cells followed the method outlined in the materials and methods
section however no farnesol was added at this stage. A flow-through system was setup up where
fresh LB Miller media maintained at 37°C and was passed through the lumen of a Bard Bardex®
Foley All-Silicone 16 French urinary catheter. A schematic of the experimental setup is
presented in figure 10. First the lumen was inoculated with 5 ml of mid-log phase cells of P.
aeruginosa PAO1 with an approximate OD600 nm of 0.7 with a sterile syringe. A sterility check
was performed of the effluent to ensure that only P. aeruginosa was present in the lumen.
Following seeding, fresh sterile media was passed in one direction through the lumen. The flow
rate was adjusted so that the cells were unable to grow upstream of the catheter segment with a
Masterflex® pump (Cole Parmer model 7518-10) set at a flow rate of 20 ml/min with Masterflex®
Tygon tubing (06409-15). All connections were maintained with tubing clamps that insured no
liquid media leaked. The urinary catheter was allowed to sit for two days to allow the cells to
develop a mat along the lumen of the catheter before exposure to farnesol occurred. Once the
biofilm had fully developed the catheter containing the biofilm was removed from the flowthrough system and was connected to two sterile 10 ml syringes that contained 250 µM E,E57

farnesol. One of the syringes was completely filled with medium and the other was completely
empty. In order to expose the cells to the farnesol without disturbing the biofilm, the media was
slowly released from the full syringe and equal pressure was used to suction the media into the
empty syring. Once the previously empty syringe was full with approximately 10 ml of media
the process was repeated in the other direction. This process was repeated once every 10
minutes for two hours. At the completion of the two-hour exposure the media was forcefully
pushed from the syringe through the catheter and the cells were expelled into a 50 ml falcon
tube. The media was then drawn up again and was used to forcefully wash the cells from the
lumen of the catheter. The cells that remained in the lumen were removed by placing the
catheter segment into a fresh 15 ml falcon tube with 11 ml of sterile PBS and vortexing until the
thin layer of cells were removed. The lumen segment was removed and the tube was centrifuged
at 10,000 RPM for 10 minutes to pellet the cell material that was washed from the lumen. This
pellet was then combined with the previously aquired aspirate from the lumen. The protocol for
cell harvesting, as outlined previously in the materials and methods section, was followed to
prepare the cells for lysis and proteomic study.
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Figure 12: Diagram of experimental set-up for flow-through biofilm
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Figure 12: Graphical depiction of the experimental set up for the flow through biofilm model.
The flow of media was in a single direction to ensure that fresh media was continuously provided
to the developing biofilm.
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Experiment 5: P. aeruginosa PAO1 co-cultivation with C. albicans whole cells, IPG range 3-7
The cells used in this experiment were removed from glycerol stock and initial cultures
were established according to the procedures outlined previously in the Materials and Methods
section. Both organisms used, P. aeruginosa PAO1 and C. albicans SC5314, were initially
grown in LB Miller broth at 37°C and 130 RPM. First both strains were grown to mid-log phase
(an OD600 of 0.7 for PA and an OD600 of 1 for CA) and 1 ml was removed from each culture.
This sub-sample was centrifuged at 10,000 RPM for 10 minutes at 4°C. Following
centrifugation the supernatant was discarded and was replaced with fresh PBS, at which time the
pellet was dispersed with vortexing. This process was repeated three times to remove any
residual medium. The cell pellets were resuspended in 500 µl of sterile PBS. 250 µl of each
organism was used to inoculate a common flask with 100 ml of pre-warmed sterile LB Miller
media that contained both P. aeruginosa and C. albicans after inculation. Then the remaining
250 µl was used to inoculate a second flask, which also contained 100 ml of pre-warmed sterile
LB Miller media that was only P. aeruginosa or C. albicans after inoculation. These flasks were
allowed to grow for 8 hours at 37°C and 130 RPM and were then immediately put on ice
following the 8 hour incubation. The cells were then harvested according to the harvesting
protocol described previously and the resulting cell pellets were placed on ice for one hour to
ensure thorough chilling. After one hour, the individual pellets of P. aeruginosa and C. albicans
were combined by first resuspending the pellet in 2 ml of chilled sterile PBS and then the slurry
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was combined into one centrifuge bottle and centrifuged at 4°C at 10,000 RPM for 10 minutes.
The supernatant was removed and the wet weight of each pellet from the combined cultures was
measured. The cells were then lysed according to the procedure outlined previously in the
Materials and Methods section to prepare the samples for proteomic analysis. The sonication
was optimized to preferentially lyse the bacterial cells without complete lysis of the yeast cells.
In order to fully lyse yeast cells extended sonication times with the presence of glass beads are
required.
Growth on E,E-farnesol and alternative carbon sources:
Two experiments were performed to determine the ability of P. aeruginosa to grow on
E,E-farnesol as a sole carbon source. Second to determine the ability of different long chain
carbon compounds to prime the metabolism of P. aeruginosa to utilize E,E-farnesol as a carbon
source. Liquid media and solid media were prepared with Stanier’s minimal medium to which
alternate carbon and nitrogen sources were added. The carbon sources assayed for growth were:
glucose, sorbitol, sodium- acetate, hexanoic acid, hexanoamide, and octanoic acid. The nitrogen
source used was ammonium sulfate. Both plates and liquid media were made with 1000 ppm
carbon source and 1000 ppm nitrogen source. P. aeruginosa PAO1 was tested for the
appearance of colonies for plates and turbidity for liquid media. PAO1 cells were removed from
glycerol stocks and allowed to thaw. Once thawed, 10 µl was removed and placed into 10 ml of
sterile LB Miller media. The media was vortexed to allow even dispersion of cells in the liquid
media. 10 µl was then pipetted into LB Miller plates and spread with a sterile glass spreader.
The plates were allowed to incubate at 37°C overnight. The following morning the plates were
checked for sterility, scraped, and used to inoculate liquid Stanier’s medium with glucose as the
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carbon source. 200 ml of liquid Stanier’s medium was inoculated with one loop full of P.
aeruginosa PAO1 and allowed to shake at 150 RPM and 37°C for 8 hours or to an OD600 of 0.8
to create a working culture. For the solid media experiments 10 µl was removed from the
working culture and spread on the surface of each medium type. The plates were allowed to
incubate overnight at 37°C. They were rated according to the density and number of colonies
present on the plate surface present following overnight growth. For the liquid media
experiments, 10 µl was removed from the working culture and was inoculated into 990 ml of test
media. Three replicates were made of each media type. The baffled flasks were allowed to
incubate overnight at 37°C and 150 RPM for approximately 16 hours. The flasks were assayed
for turbidity and the OD600 was determined using with 1 ml samples. The 16 hour culture was
diluted into fresh test medium and the OD600 was measured hourly to generate a growth curve.
Each flask was inoculated with a starting OD600 of 0.02 and was allowed to incubate at 37°C and
150 RPM.
Low-osmolarity growth:
P. aeruginosa PAO1 was inoculated from glycerol stocks with 10 µl into 10 ml of sterile
LB Miller media. The media was vortexed until the cells were fully dispersed. 10 µl of the first
past stock was used to inoculate 99 ml of LB Miller media. The baffled flask was allowed to
incubate at 37°C and 150 RPM overnight for approximately 16 hours. The low osmolarity
medium was based on LB medium and contained tryptone and yeast extract but no sodium
chloride. After 16 hours the P. aeruginosa cells were exposed to 250 µM farnesol or to the
methanol only as a control for 8 hours. The cultures were then split where half of the cells in
62

each condition were exposed to high osmolarity LB and low osmolarity LB. There were three
replicates for each media condition.
C. elegans virulence assay
The assay for fast killing of C. elegans by P. aeruginosa requires a high salt growth
medium. The high osmolarity PGS media was used (see appendix), and fast killing was scored
after 8 hours. E. coli 0P50 that does not kill C. elegans, was used as a control. Glycerol stocks of
E. coli 0P50 were obtained from Dr. W.W. Walthall’s collection at Georgia State University and
were grown according to the method described in the strains and cultivation section. P.
aeruginosa and E.coli cultures were first grown overnight in 100 ml of LB-Miller broth at 130
RPM and 37°C. A 10 µl disposable inoculating loop was used to create a lawn of bacterial cells
on the high osmolarity PGS agar plates. The plates were allowed to incubate at 37°C for 16
hours and 24 hours at 25°C. Then the plates were seeded with 20-30 L4 stage C. elegans
(provided by Dr. W.W. Walthall, Georgia State University). The plates were observed under a
dissection scope to quantify the exact number of C. elegans present on each plate. The plates
were then allowed to incubate at 25°C for eight hours in the dark. After eight hours the number
of live C. elegans were quantified. Live C. elegans were defined as exhibiting movement across
the bacterial lawn or movement once touched with a hair-thin metal probe. C. elegans were
counted as dead if they exhibited no movement upon stimulus. The number of survivors at the
end of eight hours was used to determine the percent mortality when compared to deceased.
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MIC assay- Tobramycin
A stock solution of Tobramycin (Sigma T-1783) with a concentration of 100 mM was
made in 50 ml of sterile water. The stock solution was then aliquoted into 5 ml volumes and
stored at -20°C until thawed for use. A working solution of 50 mM was made just before use in
the assay with sterile water. Cells of P. aeruginosa GSU3 were removed from glycerol stock
and inoculated into 100 ml of sterile LB Miller media and allowed to incubate for 16 hours at
37°C and 150 RPM. The MIC assay was performed in Costar® (catalog no. 3473) 24 flat bottom
microtiter plates. The total volume for each well was 1 ml. In each well the final volume was
adjusted with sterile LB Miller media. The volume of DMSO + E,E-farnesol working solution
was made by making a 1:10 dilution of 3.8 M stock E,E-farnesol solution (100 µl into 900 µl of
DMSO). The two conditions tested were, GSU3 cells exposed to 250 µM E,E-farnesol
solubilized in DMSO and GSU3 cells that were only exposed to DMSO (66 µl) . Each condition
was exposed to a range of Tobramycin concentrations that were shown in the literature to be
effective in inhibiting the growth of GSU3. The concentrations tested were 0.5 µg/ml, 0.75
µg/ml, 1 µg/ml, 1.5 µg/ml. One row was used to test the effects on growth of no Tobramycin on
each condition. One row was used to determine the changes in OD that may be caused by
compositional changes in the culture medium for each condition. All components were present
without any cell culture. The wells were set-up as reported in the following table:
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Table 5: Sample organization for MIC assay
Row

Dilution
µg Tobramycin /

Volume

Volume DMSO

Volume blank

Tobramycin

+ E,E-farnesol:

media

µl working solution

250 µM stock

(ml)

Volume inoculum
(µl)

ml

(µl)
1

0

0

6.6

990

5

2

0.5

5

6.6

984

5

3

0.75

7.5

6.6

981

5

4

1

10

6.6

978

5

5

1.5

15

6.6

974

5

Table 5: Organization of samples in a 24 well microtiter plate for incubation and growth in the Tobramycin MIC
assay. Each row had different concentrations of Tobramycin while the volume for farnesol and inoculum remained
the same.
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Imaging cell morphology
Cells from the tobramycin MIC assay were imaged to better capture observed changes in
morphology that occurred during the assay. The cells (P. aeruginosa GSU3) were imaged in 24well microtiter plates. These plates were imaged by Dr. Simmons (Georgia State University)
using the DeltaVision® microscope system, (Applied Precision, LLC., Issaquah, WA.)
Pyruvate dehydrogenase activity assay
Cells of P. aeruginosa were lysed according to the proteomics protocol with the exception
that the lysis buffer used was sterile 50 mM phosphate buffered saline and were stored at -80°C.
The cells were thawed at room temperature and kept on ice once completely thawed. The
concentration of total protein was quantified using the 2D Quant Kit (GE Healthcare, Piscataway
NJ) following manufacturers protocol and the final concentration was adjusted to 1 µg/µl with 50
mM PBS for each sample. 500 µg of total protein was used for each sample that was tested.
Three conditions were set up to establish adequate controls: reaction mixture without pyruvate
and 500 µg sample protein, reaction mixture with 50 mM pyruvate and 500 µg sample protein,
reaction mixture with 100 mM pyruvate and 500 µg sample protein. The reaction mixture was
composed of 2.5 mM NAD, 0.2 mM thiamine pyrophosphate, 0.1 mM Coenzyme A (Sigma
Aldrich), 0.3 mM DTT, 1 mM Magnesium chloride (Sigma Aldrich), .6 mM INT
(Iodonitrotetrazolium violet) (Sigma Aldrich). This solution was made up in 10X solution to
accommodate small masses of additives and the solution was stored at 4°C until ready for use. A
stock solution of 5 mM pyruvate was also made and stored at 4°C until ready for use. The same
volume of crude enzyme extract was added into each reaction vial (3 replicates per sample).
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Then a base line absorbance at OD500 was recorded before the pyruvate was added. This value
was subtracted from each sample to determine the difference in slope between the control and
experimental conditions. To start the reaction an appropriate volume of 5 mM pyruvate was
added. In order to get the correct concentration of the reaction mixture, pyruvate solution, and
protein concentration the solutions were made up in the following manner. Total working
volume in each reaction vial was 1.5 ml. A sterile clean 5 ml test tube was used. First 150 µl of
the 10X reaction mixture was added to the test tube. Then 375 µl of the 4X pyruvate solution
was added to the test tube. Then the volume of crude sample needed to add the same
concentration of total protein to each vial was calculated and added. The total volume of
reaction mixture, pyruvate solution, and crude protein solution used was added together and this
value was subtracted from 1.5 to determine the volume of water to add to make the total volume
of each sample 1.5 ml. Before the pyruvate solution was added the optical density was recorded
of one of the samples to obtain a blank base-line value. Once the reaction was started, 300 µl
was removed and placed into a 96-well plate the absorbance was read at OD490 in the Victor
(Perkin-Elmer, Wellesley, MA) and 1 ml was assayed for absorbance in the Turner at OD500. The
Victor was programmed to take an OD reading every second for three minutes for each
individual well. The reading in the Turner was taken every 10 seconds for three minutes. All
timing for reactions began once the reaction mixture was added.
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Results

Overview
The goal of this project was to determine the effects exposure to E,E-farnesol had on the
expression proteome of P. aeruginosa. The approach taken was to utilize two-dimensional gel
electrophoresis based proteomics to identify proteins which showed significant differences in
abundance as a result of exposure to E,E-farnesol within the cytosol of P. aeruginosa. Two
studies employed Differential In-Gel Electrophoresis (DIGE) techniques while the remainder
were based on a two-dimensional Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis
(SDS-PAGE). Once proteins of interest (those proteins that showed a significant change {Pvalue ≤ 0.05} in abundance {average ratio +/- ≤ 0.05}) were found, assays to validate the
findings were used to put the results from the proteomics data into physiological context. In
each of the proteomics studies, the goal was to identify spots that corresponded to proteins that
exhibited a statistically significant and biologically relevant change in abundance. Protein spots
that exhibited an average value of +/- .05 and a p-value of .05 or less were considered to be
statistically significant.
The statistical tests to obtain an average value and a p-value were performed using the
statistical tool function provided in ImageMaster or in DeCyder. The p-value was employed to
establish statistical significance of the change in abundance across all of the biological and
experimental replicates. The average value is a measure of the change in abundance of a
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particular protein spot. A positive average value indicates an increase in abundance while a
negative average value indicates a decrease in abundance.
The results reported from the image analysis software were in the form of 3D
topographical images. The graphical image of the gel was generated by DeCyder® version 5.
(The 3-D graphical image is a topographical representation of pixel intensity present in the gels
that were excited by the specific wavelengths for the particular CyDye® label used. The 3D
images are provided to better visualize the differences in abundance as peak height and volume,
and to provide a visual comparison of adjacent protein spots. Also included in the data report
from the spots identified with DeCyder® version 6.5 was the distribution graph that displayed the
change in abundance in all of the samples within the data set. The x-axis of the distribution
graph reports the particular condition that was tested, and the y-axis reports the standardized log
abundance. The standardized log abundance is calculated from the Cy2 standard that is present
in each DIGE study. With the 3D topographical image and distribution graph it is then possible
to easily visualize the relationship between each individual gel. The mean is also present in the
distribution graph to highlight the overall trends present in the data for a particular condition to
more easily visualize increases or decreases in abundance.
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Experiment 1: Exposure of P. aeruginosa PAO1 to mixed isomers of 30 µM farnesol in the
pI range of 3-11
Figure 13 reports a protein of significance from the initial proteomics study with farnesol.
This study focused on the effect of P. aeruginosa PAO1 exposed to 30 µM farnesol. The
farnesol used was a racemic mixture and was not solubilized in a solvent prior to addition to the
broth culture of P. aeruginosa. Protein peak C2 shows a significant decrease in abundance even
though the nearest neighbors show an increase in abundance (A2 and B2) when compared to the
control that was not treated with farnesol. Peak C2 decreased in peak height as well as peak
volume as compared to peak C1. This protein was selected for MS analysis because its average
ratio was > +/- 2.0 and exhibited a p-value less than .05. MALDI TOF-TOF analysis identified
peak C2 as Flagellin type B from P. aeruginosa.
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Figure 13: DeCyder image of Flagellin B as subsuquently identified by proteomic analysis
of P. aeruginosa PAO1 with 30 µM racemic farnesol in the pI range of 3-11

A1
B1

A2
C1

B2

No farnesol

C2

30 uM farnesol
Flagellin type B

Average Volume
-2.07
p-value
7.10E-06

Figure 13: 3D image from DeCyder that displays a decrease in abundance in P. aeruginosa PAO1 exposed to 30
µM racemic farnesol.
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Experiment 2: P. aeruginosa PAO1 and GSU3 exposed to 25 µM and 250 µM E,E-farnesol,
pI 3-11
The results presented in figure 14 were generated in the DIGE study where two different
concentrations of farnesol (25 µM and 250 µM) and two different strains of P. aeruginosa
(PAO1 and GSU3) were analyzed. Peak A2 demonstrates an increase in abundance in peak
height and in peak volume. The most evident chance in abundance is the peak base area. The
increase in A2 is evident despite the decrease in abundance of the near neighbor peak B2 as
compared to the control B1. The protein spot (identified by MS analysis to be GMP synthase)
exhibited an increase in abundance (1.62) in the cells of both strains that were exposed to
farnesol, at both doses. There was no statistically significant difference in GMP synthase
abundance levels between the two different strains when exposed to either 25 or 250 µM E,Efarnesol. At 250 µM levels of E,E-farnesol the mean lines for both strains cross indicating no
significant difference in abundance between the two strains.
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Figure 14: DeCyder image of GMP synthase as subsequently identified by proteomic
analysis of P. aeruginosa PAO1 and GSU3, pI 3-11.

control

E,E-farnesol exposed

B1

A1

B2
A2

Figure 14: Results from DeCyder®version 5 to determine the effects that 250 µM E,E-farnesol has on two strains of
P. aeruginosa PAO1 and GSU3. These results show that there is a statistically significant increase in both strains
for GMP synthase as compared to cells of the same type that were not exposed to E,E-farnesol. The average ratio
was 1.62 and the p-value was .002.

The results presented in figure 15, which are also from experiment 2, show the change in
abundance for the protein spot (that was later identified by MS analysis to be dihyrolipoamide
dehydrogenase). This protein exhibited an average value of -1.19 and a p-value of .007.
Interestingly, the trend appears when observing the distribution graph that a closer grouping of
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decrease in abundance is present in the cells of PAO1 and GSU3 that were exposed to 25 µM
E,E-farnesol seen when the cells were exposed to 250 µM E,E-farnesol do not present as
condensed results and some of the biological replicates show a less marked decrease in
abundance when compared to the control.
Figure 15: DeCyder image of Dihydrolipoamide dehydrogenase identified by proteomic
analysis of P. aeruginosa PAO1 and GSU3.

control

A1

E,E-farnesol exposed

C1
B1

A2
D1

B2

C2

D2

Figure 14: Results from DeCyder®version 5 to determine the effects that 250 µM E,E-farnesol has on two strains of
P. aeruginosa PA01 and GSU3. These results show that there is a statistically significant decrease in both strains as
compared to cells of the same type that were not exposed to E,E-farnesol. The average ratio was -1.19 and had a pvalue of .007.
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Experiment 3: Planktonic P. aeruginosa PAO1 exposed to 25 µM E,E-farnesol, pI range
4.5-5.5
The data presented in table 6 are a summary of all protein spots that were identified as
proteins of interest in the DIGE study that focused on the pI range of 4.5-5.5 for the effects of
E,E-farnesol on P. aeruginosa and which were subsequently identified through MS. Table 6
reports the name and accession number for each protein along with the p-value, average ratio,
theoretical pI, theoretical molecular weight, and a summary of its function within the cell.
Statistical graphs and 3D topographical views of these proteins of interest identified through MS
analysis were a) ATPase PilB, b) major porin and structural outer membrane porin OprF
precursor, c) Aconitase B, d) amidase, e) NAD-dependent glutamate dehydrogenase, f) Chain A,
structure of Arginine Deiminase, g) outer membrane protein and related peptidoglycanassociated (lipo)proteins and are shown in Figures 1-5 respectively.
In each of the graphical images, the 3D image shown on the left is from the control
samples and the 3D image on the right was from the E,E-farnesol exposed cells. The statistical
graph provides the experimental conditions on the x- axis and the standardized log abundance on
the y-axis. Also present on the graph is the mean of standardized log abundance of each of the
samples in the study. Each individual circle on the graph represents one gel and the standardized
log abundance of the matched spot.
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Table 6: Summary of identified proteins by proteomic analysis of P. aeruginosa PAO1
exposed to 25 µM E,E-farnesol in IPG range of 4.5 to 5.5
MS ID
ATPase PilB, Type II secratory pathway,
ATPase PulE/Tfp pilus assembly

p-value
.0099

Average ratio
-2.50

pI
4.85

MW (Da)
56424.28

FXN
Cell motility and
secretion

.0049

-1.83

5.72

41629

Metabolism

.0083

-1.97

5.0

37640

Secretion and
membrane
stability

.024*

1.78

5.37

94185.43

.016*

-1.63

4.42

23594.86

Central
metabolism
TCA cycle
Membrane
spanning region
of OprF

hypothetical protein PaerPA_01001051
[Pseudomonas aeruginosa PACS2]

.014*

-1.65

Unk

Unk

Unk

amidase
gi|15599358

.0023

1.52

5.8

38000

metabolism

hypothetical protein PaerP_01000692
[Pseudomonas aeruginosa PA7]

.0048

1.50

Unk

Unk

Unk

ABC-type multi-drug transport system,
ATPase and permease components

.0039

-1.51

5.25

67620

Defense
mechanism

.0023

-1.53

4.8

48000

Amino acid
metabolism

.039*

-1.53

5.08

46069.98

.015*

-1.54

4.42

23594.86

Metabolism of
amino acids and
related molecules
Membrane
spanning region
of OprF

.0023

-1.59

Unk

Unk

ZP_00972151
Pyruvate dehydrogenase complex,
dehydrogenase component E1
ZP_00971965
Major porin and structural outer
membrane porin OprF precursor
COG2885
gi|84321510
COG1049: Aconitase B
ZP_0097612
peptidoglycan-associated (lipo)proteins
gi|84321510
COG2885

ZP_00968441
NAD-dependent glutamate
dehydrogenase[Pseudomonas aeruginosa
PAO1]
gi|15598264
Chain A, Structure Of Arginine Deiminase
gi|42543632
COG2885: Outer membrane protein and
related peptidoglycan-associated
(lipo)proteins [Pseudomonasaeruginosa
C3719]
gi|84321510
hypothetical protein PaerPA_01000945
[Pseudomonasaeruginosa PACS2]

Unk

Table 6: Table summarizing proteins identified by DeCyder and MS analysis that was statistically significant. This table
reports the MS identity, average ratio, p-value, pI, molecular weight, and summarized function. Shaded rows indicate
proteins that are presented more in-depth in Figures 1-5.
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Figure 16:DeCyder image of ATPase PilB identified by proteomic analysis of P. aeruginosa
PAO1 exposed to 25 µM E,E-farnesol.

control

25 µM E,E-farnesol

Figure 16: 3D topographical image and standardized log abundance generated by DeCyder®version 6

Result show that 25 µM E,E-farnesol affected planktonic P. aeruginosa PAO1. These results
showed a statistically significant decrease (p-value .0099) and (fold change -2.5) in ATPase PilB
as compared to PAO1 cells that were not exposed to E,E-farnesol. The mean of the experimental
values is approximately -0.3 while the mean of the control values is approximately 0.2.
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Figure 17: DeCyder image of Major porin and structural outer membrane porin OprF
precursor as identified by proteomic analysis of P. aeruginosa PAO1 exposed to 25 µM
E,E-farnesol.

control

25 µM E,E-farnesol

Figure 17: 3D topographical image and standardized log abundance generated by DeCyder®version 6

Result show that 25 µM E,E-farnesol affected the abundance of OprF precursors within the
cytosol in planktonic P. aeruginosa PAO1. These results showed that there is a statistically
significant decrease (p-value .0083 and fold change of -1.97) in OprF precursor as compared to
cells of the same type that were not exposed to E,E-farnesol.
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Figure 18: DeCyder image of Amidase as identified by proteomic analysis of P. aeruginosa
PAO1 exposed to 25 µM E,E-farnesol

control

25 µM E,E-farnesol

Figure 18: 3D topographical image and standardized log abundance generated by DeCyder® version 6

Result show that 25 µM E,E-farnesol affected the abundance of amidase within the cytosol in
planktonic P. aeruginosa PAO1. These results showed that there is a statistically significant
increase (p-value .0023) and fold change (+ 1.52) in amidase as compared to cells of the same
type that were not exposed to E,E-farnesol.
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Figure 19: DeCyder image of Arginine diminase as identified by proteomic analysis of P.
aeruginosa PAO1 exposed to 25 µM E,E-farnesol

control

25 µM E,E-farnesol

Figure 19: 3D topographical image and standardized log abundance generated by DeCyder® version 6

Result show that 25 µM E,E-farnesol affected the abundance of arginine diminase within the
cytosol in planktonic P. aeruginosa PAO1. These results showed that there is a statistically
significant decrease (p-value .039) and fold change ( -1.53) in arginine diminase as compared to
cells of the same type that were not exposed to E,E-farnesol.
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Figure 20: DeCyder image of NAD-dependent glutamate dehydrogenase as identified by
proteomic analysis of P. aeruginosa PAO1 exposed to 25 µM E,E-farnesol

control

25 µM E,E-farnesol

Figure 20: 3D topographical image and standardized log abundance generated by DeCyder®version 6

Result show that 25 µM E,E-farnesol affected the abundance of NAD-dependent glutamate
dehydrogenase within the cytosol in planktonic P. aeruginosa PAO1. These results showed that
there is a statistically significant decrease (p-value .0023) and fold change (-1.53) in NADdependent glutamate dehydrogenase as compared to cells of the same type that were not exposed
to E,E-farnesol.
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Figure 21: DeCyder image of Pore region OprF (Outer membrane protein and
related peptidoglycan-associated (lipo)proteins as identified by proteomic analysis of P.
aeruginosa PAO1 exposed to 25 µM E,E-farnesol

control

25 µM E,E-farnesol

Figure 21: 3D topographical image and standardized log abundance generated by DeCyder®version 6

Result show that 25 µM E,E-farnesol affected the abundance of pore region of OprF within the
cytosol in planktonic P. aeruginosa PAO1. These results showed that there is a statistically
significant decrease (p-value .015) and fold change (-1.54) in pore region OprF as compared to
cells of the same type that were not exposed to E,E-farnesol.
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Figure 22: DeCyder image of Aconitase as identified by proteomic analysis of P. aeruginosa
PAO1 exposed to 25 µM E,E-farnesol

control

25 µM E,E-farnesol

Figure 22: 3D topographical image and standardized log abundance generated by DeCyder®version 6

Result shows that 25 µM E,E-farnesol affected the abundance of aconitase within the cytosol in
planktonic P. aeruginosa PAO1. These results showed that there is a statistically significant
decrease (p-value .015) and fold change (-1.54) in aconitase as compared to cells of the same
type that were not exposed to E,E-farnesol.
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Experiment 4: Exposure of Biofilm P. aeruginosa PAO1 to 250 mM farnesol in the pI range
of 3-11

Table 7 presents the results from the proteomics experiment where P. aeruginosa PAO1
cells were grown as a biofilm in the lumen of a Bard Bardex® All-Silicone Urinary Foley
catheter. The fully developed biofilm, as defined by a consistent blanket of cell growth on all
sides of the lumen, was exposed to fresh media containing 250 µM E,E-farnesol. The proteins
were extracted using the proteomics protocols detailed in the materials and methods section and
were analyzed for abundance changes using 2D SDS PAGE gels. The gels were analyzed using
ImageMaster® Platinum (GE Healthcare). The proteins of interest were identified using the
histogram function to identify proteins that exhibited an increase or decrease in pixel intensity as
compared to the control gels. A limited number of gels were available for analysis due to sample
loss from gel structural integrity failure. Full statistical data was not available due to the limited
number of samples (< 6). The histogram function allowed for a general comparison between the
control and experimental conditions. The 3D topographical image was used to assist in the
determination that the match was accurate and that the reported fold change was accurate.
Proteins of interest were removed from the gel and identified by mass-spectrometry.
In table 7 the identity of each protein of interest is reported in the left column with the
header MS Identity. Identities were determined using MASCOT to search matches from the
identified amino acid sequence. The relative change in abundance is reported in the right hand
column and the respective fold change is reported as a downward green arrow or an upward
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orange arrow. A total of six proteins of interest were positively identified and are reported in
table 7.

Table 7: Mass-spectrometry identified proteins from proteomics project with P. aeruginosa PAO1
biofilm exposed to 250 µM E,E-farnesol.
MS Identity

Relative change in abundance exhibited
in cells exposed to 25 µM E,E-farnesol as
compared to the control

E3 subunit dihydrolipoamide
dehydrogenase
Arginine deiminase
Succinyl-CoA synthetase beta-chain
GroEL
Elongation factor Tu (GTPase)

Outer Membrane porin OprE

Table 7: Proteins identified by MALDI-TOF-TOF MS and MASCOT database search. Protein spots of interest identified
with ImageMaster Platinum analysis software.
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Experiment 5: Proteomic analysis of Co-culture of P. aeruginosa PAO1 with Candida
albicans in the pI range of 3-11

Table 8 presents results from the proteomics experiment where P. aeruginosa PAO1 cells
were grown in co-culture with C. albicans. Pure cultures of both microorganisms were grown to
a specific OD600 nm (see materials and methods section for details) then the cultures were mixed
in fresh medium. The co-cultured cells were harvested and their proteins extracted according to
the proteomics protocol and were analyzed for abundance changes using 2D SDS PAGE gels.
The gels were analyzed using ImageMaster® Platinum (GE Healthcare). The proteins of interest
were identified using the histogram function to identify proteins that exhibited an increase or
decrease in pixel intensity as compared to the control gels. The 3D topographical image was used
to determine that the match was accurate and that the reported fold change was accurate.
Proteins of interest were removed from the gel and identified by mass-spectrometry. The name
of the protein is reported in the left column with the header MS Identity. This was determined
using MASCOT to search matches from the identified amino acid sequence. The relative change
in abundance is reported in the right hand column and the respective fold change is reported as a
downward green arrow or an upward orange arrow. The proteins that exhibited a decrease in
abundance in the experimental condition have a downward green arrow. The proteins that
exhibited an increase in abundance in the experimental condition have an upward orange arrow.
A total of four proteins of interest were positively identified and are shown in table 8.
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Table 8: Mass-spectrometry identified proteins from proteomic analysis of co-culture
between P. aeruginosa PAO1 and C. albicans SC5314.

Putative copper transport outer membrane
porin OprC precursor
COG2235: Arginine deiminase
COG1064: Zn-dependent alcohol
dehydrogenase
Conserved hypothetical protein

Table 8: Proteins identified by MALDI-TOF-TOF MS and MASCOT database search. Protein spots of interest identified
with ImageMaster Platinum analysis software.
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Figure 23: Illustration of proteins found in common in Biofilm, Co-culture, and Planktonic
experimental conditions

Biofilm

Co-culture

OprC

OprE

Arginine
Deiminase
DLDH

OprF

Planktonic
Figure 23: Proteins identified that were present in two or more physiological conditions. The direction of the black arrow indicated the change in
abundance.
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Physiological tests to validate proteomics findings

Osmotic Stress Assay

To place the proteomics findings in a physiological context the effect that E,E-farnesol
had on the ability of the cell to withstand osmotic stress was assayed. The purpose of this assay
was to determine if the decrease in abundance of porin precursors in the cytosol could lead to a
destabilization of the outer cell membrane and structural integrity of the cell wall. This test was
based on placing logarithmic growth phase P. aeruginosa cells into low osmolarity LB medium.
The ability of the cells to withstand stress was assayed using optical density at 600 nm. A
growth curve was recorded on samples in triplicate for each condition for six hours. Over the
course of the assay there was not a significant difference in growth patterns in the control cells
that were not exposed to 250 µM E,E-farnesol.
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Table 9: Growth curve of P. aeruginosa PAO1 exposed to 250 µM E,E-farnesol under low
osmolarity conditions

Table 9: Growth curve of P. aeruginosa PAO1 exposed to 250 mM E,E-farnesol. The change in turbidity was
determined using a spectrophotometer at 600 nm.
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Fast killing virulence assay in C. elegans

The effect of exposure to farnesol on the virulence of P. aeruginosa was assayed using
the C. elegans plate virulence assay. The two plate types used were those made with spent
medium from C. albicans and those without. In order to determine the percent mortality from
the C. elegans plate assay the number of animals that survived was subtracted from the initial
inoculum value. Then the percentage of those that did not survive was determined from the
number of survivors. The results presented in table 30 represent the percent mortality for the
assay. P. aeruginosa PAO1 cells that were grown without any components from C. albicans
caused a mortality rate in C. elegans of 56 %. When P. aeruginosa was grown on plates that did
have components from C. albicans the mortality rate was slightly higher than the control but was
significantly lower than the P. aeruginosa cells alone. The mortality rate for the control strain E.
coli cells was on average 18.5 % this was due to the animals sticking to the edge of the plate.
Based on these results the presence of farnesol containing spend medium from C. albicans does
have a role in reducing the virulence of P. aeruginosa in the fast killing C. elegans assay.
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Table 10: Effect of E,E-farnesol on P. aeruginosa PAO1 virulence in C. elegans fast killing
assay

spent medium

E. coli OP50

spent medium

P. aeruginosa PAO1

Table 10: Results from fast killing assay with C. elegans. Agar plates were made that were spiked with spent
medium from C. albicans or were only LB Miller agar. C. elegans animals were inoculated and counted. After
eight hours the animals were counted again and the number of live and dead animals were quantified. The plates
that were spiked with spent medium from C. albicans did decrease the mortality of P. aeruginosa in the fast killing
assay.
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Validation of activity of Dihydrolipoamide dehydrogenase
In order to validate the proteomics results for dihydrolipoamide dehydrogenase, a
component of the pyruvate dehydrogenase enzyme complex. The activity of pyruvate
dehdrogenase was quantitated using a colormetric assay to detect enzyme kinetics (Table 11).
The activity of pyruvate dehdrogenase was detected at the rate that iodonitrotetrazolium violet
was reduced and caused a color change. The slope of the line was used to determine if the
kinetics for cells exposed to 25 µM E, E- farnesol were significantly lower than those cells that
were not. The results show that there was not a significant difference in the slope of the line for
the to conditions.
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Table 11: Enzyme Activity of Pyruvate Dehydrogenase

Table 11: This table reports the data from the Pyruvate dehydrogenase activity assay. The enzyme kinetics is based
on the slope of the line. The absorbance of this assay is measured at 37 degrees Celsius and pH 7 at 490 nm using
the Victor spectrophotometer. The assay begins colorless and as NADH is produced tetrazolium purple is reduced
and causes a darker color change that can be measured. The greater the degree of color change in less time is the
greater the speed of the enzyme. The slope of both lines was determined to be .0008 using Excel’s regression tool.
The similarity in slope of both conditions does not show any difference in the enzyme activity of Pyruvate
Dehydrogenase in either condition.

Antibiotic susceptibility to tobramycin in P. aeruginosa cells exposed to E,E-farnesol

In order to validate the results for a decrease in abundance of OprF the ability of E, Efarnesol to affect the susceptibility of P. aeruginosa GSU3 to Tobramycin was assayed. This
assay tested P. aeruginosa against a range of concentrations from .2 to 1.5 µg/ ml of
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Tobramycin. The red line represents the control where cells were not spiked with E, E-farnesol
during the experiment. The blue line represents the experimental condition where cells were
exposed to 250 µM E,E-farnesol. The ability of the cells to survive was determined by turbidity
measurements at 600 nm using the Victor spectrophotometer. It appears that at lower
concentrations the turbidity of the cultures exposed to E,E-farnesol is higher than the control.
However, at approximately 0.8 µg/ ml the turbidity experiences a dramatic drop and the cells that
were exposed to farnesol are more susceptible to Tobramycin than the control.
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Table 12: The effect of exposure to 250 µM E,E-farnesol on antibiotic susceptibility in P.
aeruginosa PAO1

control
E,E-farnesol

Table 12: Minimum inhibitory concentration assay to test level of susceptibility of P. aeruginosa GSU3 to
Tobramycin.

Microscopy of P. aeruginosa cells exposed to tobramycin with or without E,E-farnesol

At the completion of the MIC assay it was apparent that the colonal morphology of the
cells in the two different treatment conditions exhibited distinct differences. The colonies
floating on the surface were imaged by microscopy by Dr. Robert Simmons at Georgia State
University. The cells exposed to 250 µM E,E-farnesol exhibited a very diffuse morphology
while the control cells had a very condensed group of cells at the center of the broth.
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Figure 24: Image of P. aeruginosa GSU3 exposed to 250 µM E,E-farnesol and 0.8 µg/ ml
Tobramycin

Figure 24: Microscopic image of colonal morphology of cells in broth containing 250 µM E,E-farnesol and 0.8
µg/ ml Tobramycin
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Figure 25: Image of P. aeruginosa GSU3 exposed 0.8 µg/ ml Tobramycin

Figure 25: Microscopic image of colonal morphology of cells in broth 0.8 µg/ ml Tobramycin
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Discussion
Overall proteomics results
The expression proteome data for proteins with a pI range of 3-11 in P. aeruginosa cells
exposed to E,E-farnesol at 25 and 250 µM E,E-farnesol did not show a highly robust change
(fold change in average ratio > 3) in abundance. This outcome was seen in all of the experiments
in this study, regardless of the mode of exposure to E,E-farnesol or whole cells of C. albicans.
However, proteins of interest were identified that showed a statistically significant change in
abundance (a fold change in average ratio greater or equal to 2). Proteomics techniques have the
power to identify modest changes in protein abundance. This is possible due to the rigor of
experimental design when taking full advantage of CyDyes® to stain the samples and DeCyder®
software to image the gels. To determine the validity of the average ratio, in terms of statistical
significance, the p-value provided a test to demonstrate the relevance of the observed results.
This made it possible to identify proteins that exhibited a modest change in abundance but
potentially had greater physiological implications within the biological system. A great deal of
effort was placed in regulating the cell lysis and downstream protein isolation procedure in order
to reliably compare results between experiments.
In the third proteomics project, the IPG range of 4.5 to 5.5 was studied several proteins
identified had a theoretical pI that fell just outside the IPG range of the strip. Proteins that were
acidic had a pI of 4.4 (peptidoglycan –associated lipoprotein and outer membrane protein and
related peptidoglycan- associated protein). The identification of these proteins in the mass-spec
analysis could be due to modifications within the cell that shifted the experimental pI of the
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protein closer to 4.5. Although these proteins were picked from two distinct protein spots on the
gel they were identified with the same MS ID. Upon inspection of the gel the two resolvable
spots have the same molecular weight but exhibit a shift in pI, thus suggesting modifications
made to the protein while still present within the cytosol. The function of peptidoglycan –
associated lipoprotein within the cell is to form the channel region within one of the porins, most
commonly OprF, which is discussed in further detail later. Two proteins were also identified
that had a theoretical pI that was higher than the IPG range of the strip used in the experiment,
suggesting modifications that made the proteins more acidic in the experimental condition. With
a pI of 5.7, pyruvate dehydrogenase subunit E1 was identified and with a pI of 5.8, amidase was
identified. Both of these proteins are important to metabolism within the cell and modifications
were made to the protein that altered the experimentally the pI of these proteins was below the
theoretical pI.
A potential reason for the modest change in abundance of the proteins of interest may have
been the proportion of cells that were able to come into contact with E,E-farnesol directly. E,Efarnesol is a hydrophobic compound and was very difficult to effectively solubilize without a
solvent present in the solution. Methanol and DMSO were used to increase the solubility of E,Efarnesol. Numerous discrete and easily visible micelles were noted upon addition of the E,Efarnesol and solvent mixture to liquids, indicating the inability to fully solubilize E,E-farnesol
into the broth even in the presence of a solvent. Therefore, the proportion of cells within the
sample culture that had physical contact with E,E-farnesol may have been reduced as compared
to a compound that would easily solubilized and evenly diffuse throughout the sample medium.
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Individual proteins showing statistically relevant change
In order to put the results into a context that could begin to explain the response that cells
of P. aeruginosa has when exposed to E,E-farnesol a literature search was performed to
determine the role that each protein has been documented to play in normal physiology of the
cell and in virulence. Each protein of interest is introduced in terms of its function within the
cell, any significant roles in virulence, and how the findings in this study fit into the overall story
of the interaction between Pseudomonas and Candida.

GMP Synthase
Guanine Monophosphate synthase (GMP synthase) belongs to the functional class of
enzymes for amino acid biosynthesis and metabolism and for purine biosynthesis and
metabolism. In this study this protein exhibited an increase in abundance (+ 1.62) (Figure 14).
The overall function of anthranilate synthase is to act as the first biosynthetic step in tryptophan
biosynthesis. GMP synthase can be found in plants, fungi, and bacteria. In plants, anthranilate
synthase is important for the production of secondary metabolites that provide the plant
protection through the production of metabolically derived compounds such as endogenous
auxin (Niyogi, et al., 1992).
A second anthranilate synthase gene has been found in P. aeruginosa (Calfee, et al.,
2001). This second anthranilate synthase has been shown to be the first step in phenazine
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production. The role of GMP synthase in anthranilate synthase activity is very intriguing because
anthranilate synthase is very important in the production of phenazine compounds. The function
of anthranilate synthase is to convert chorismate into anthranilate. The mechanism of GMP
synthase, as a subunit of anthranilate synthase component II, acts as a potential phenazine
modifying enzyme converting phenazine-1 carboxylate → phenazine 1-carboxamide (Farrow, et
al., 2007). Anthranilate can then go on to feed the need for either tryptophan synthesis or
phenazine production.
In order to better understand the role of this enzyme in amino acid metabolism, purine
synthesis and metabolism, or even phenazine production physiological tests will be utilized to
pinpoint the exact node of action for this enzyme and how E,E-farnesol could influence its
abundance within the cytosol. It was demonstrated by Cugini et al. in 2007 that exposure to
farnesol can inhibit PQS signaling and prevents the production of pyocyanin. The data presented
here suggests a potential pathway by which farnesol could be influencing the metabolic shifts
within the cell to influence the production of pyocyanin. It is possible that the cell is increasing
the abundance of GMP synthase in order to overcome suppression lower in the metabolic
pathway that leads to the production of pyocyanin in an attempt to continue production. Future
work to better understand the relationship between exposure to E,E-farnesol and abundance of
GMP synthase to the production of pyocyanin would be to determine if GMP synthase is a
regulatory check point that can be regulated at the level of the gene, RNA transcripts, or at the
protein.
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Dihydrolipoamide dehydrogenase
Data from MS analysis of statistically significant spots in 2D DIGE SDS-PAGE gels
revealed a decrease in the enzyme dihydrolipoamide dehydrogenase in cells exposed to 25 and
250 µM E,E-farnesol in both PAO1 and GSU3 as compared to control cells that were not
exposed (Figure 15). Dihydrolipoamide dehydrogenase (DLDH) is a homodimeric flavoprotein
that reoxidizes dihydrolipoamide via NAD reduction, catalyzing the electron transfer between
pyridine nucleotides and disulfide compounds (Carothers, et al., 1989). DLDH has been found to
be an integral part of many multi-enzyme processes to fulfill the aerobic and anaerobic metabolic
needs of the cell. DLDH is present in several multi-enzyme complexes responsible for the
conversion of 2-oxo acids to acyl-coA derivative. DLDH containing multi-enzyme complexes
include: pyruvate dehydrogenase as the E3 subunit where its function is to oxidize pyruvate, 2oxo glutarate dehydrogenase where its function is to oxidize alpha-ketoglutarate, 2-oxo acid
dehydrogenase complexes where its function is to oxidize branched-chain alpha-ketoacids,
glycine clevage multienzyme complex as the L protein, acetonin dehydrogenase complex. This
system, although not present in Pseudomonas, is found in gram-positive organisms such as
Bacillus subtilis, and Clostridium magnum (Weiland, 1983; Deitrich, 1990; Kruger, et al., 1994;
Oppermann, 1994; Berg, 1997; Aevarsson, et al., 1999; Huang, et al., 1999).
DLDH is present in organisms that lack 2-oxo acid dehydrogenase complexes such as
Trypanosoma burcei and archeabacteria (Danson, et al., 1987; Danson, 1988b) but the function
is still not fully understood. Richarme and Heine reported in 1986, and Richarme reported in
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1989, that organisms that possess 2-oxo acid dehydrogenases, such as E. coli, also utilize DLDH
in the metabolism and transport of sugars such as galactose, maltose, and ribose across the
membrane. In S. pneumoniae, defective DLDH was linked to decreased capsule production that
was thought to be due to disrupted alpha-galactoside metabolism and galactose transport (Smith,
et al., 2002) cell cycle progression in fission yeast (Jang, et al., 1997), and acts as a highly
immunogenic surface antigen in Neisseria meningitidis (de la Sierra, et al., 1997; Exposito, et
al., 1999).
One goal of the project was to validate a decrease in Pyruvate dehydrogenase (PD) activity
in PAO1 cells grown in the presence of 25 µM E,E-farnesol. The PD enzyme is composed of
three subunits: E1 pyruvate decarboxylase, E2 lipoyl reductase, and E3 dihydrolipoyl
dehydrogenase. Physiological tests to evaluate the role of dihydrolipoamide dehydrogenase were
performed by measuring the overall activity of the intact enzyme complex pyruvate
dehydrogenase. The results from the assay indicated that there was no difference in the enzyme
kinetics in cells that were exposed to 25 µM E,E-farnesol as compared to cells that were not
exposed. The conclusion can be made that the change in abundance of the E3 subunit caused by
exposure to 25 µM E,E-farnesol does not have an impact on the overall activity of pyruvate
dehydrogenase. According to the literature, dihydrolipoamide dehydrogenase does play an
important role in alpha-ketoglutarate, 2-oxoglutarate dehydrogenase, and branched chain alphaketo acid degradation. It is possible to exclude the role that DLDH plays in pyruvate
dehydrogenase as a point where a decrease in abundance of DLDH in response to exposure to
E,E-farnesol would have an affect. This finding is also supported in the literature because it has
been demonstrated that exposure to farnesol does not affect the survivability or growth rate of P.
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aeruginosa. If there were a decrease in pyruvate dehydrogenase activity this would severely
impact the ability of cells to utilize glucose as a source of carbon. If this enzyme were affected
there should be measurable shifts in growth rate as the cell had to adjust its metabolism to obtain
carbon from other sources than glucose.
Future directions to determine the role of a decrease in abundance of DLDH are to explore
the functionality of other enzymes that rely on DLDH as a subunit. A strong candidate is 2oxoglutarate dehydrogenase that is important in the degradation of phenylalanine. 2oxoglutarate dehydrogenase is responsible for converting L-tyrosine into phydroxyphenylpyruvate. This metabolic pathway is significant for the production of phenazine
compounds. The aromatic portion of phenylalanine is utilized in the phenazine backbone. A
possible explanation for the decrease in abundance in DLDH in the cells exposed to E,E-farnesol
may be that two isoenzymes for DLDH are found in Pseudomonas species where one is
responsible for activity in central metabolism and the second plays a role in phenazine
production (Carothers, et al., 1989). An enzyme assay, such as the one performed to determine
activity of PD, would not reflect the global effects of the enzyme subunit as it functions in
multiple distinct pathways within the cell in both central and secondary metabolism.
Dacheux et al. identified pyruvate dehydrogenase as an important player in the Type III
secretion system (TTSS) in P. aeruginosa. P. aeruginosa relies on export systems to secrete
virulence factors that aid in defense against the host immune system and for the infection
process. The TTSS is activated by a depletion of calcium in vitro. The role of PD in the TTSS
was first determined by creating mutants that were deficient in Type III secretion and identifying
genes that were disrupted. Based on the results of this assay it was found that in 14 out of the 25
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isolated TTSS-mutants the operon for pyruvate dehydrogenase (aceAB operon) was affected. It
was determined from this result that the role of PD in the induction of the TTSS was to allow
expression of the operon exsA, which is a part of the operon for the Type III secretion system.
This relationship was validated with a plasmid that fused the exsCBA promoter to the gfp gene.
If exsAB is expressed there will be detectable fluorescence. In PD mutants the exsCBA
promoter was not activated in response to calcium depletion. Virulence of PD mutants was
tested using rat models of pneumonia to compare the mutant’s virulence with that of wild-type
PA with intact pyruvate dehydrogenase complexes. Wild type strains resulted in 100% mortality
while mutants in both PD and other operons of the TTSS had a 0% mortality rate. A future
direction for this project in this area would be to determine if exposure to E,E-farnesol could
affect the expression of the TTSS genes and the production of secretion products.

ATPase PilB
This protein demonstrated a decrease in abundance (-2.5 fold change) (Figure 16) in
planktonic cells of P. aeruginosa PAO1 exposed to 25 µM E,E-farnesol. The significance of this
finding is based on ATPase’s role in facilitating pili assembly by providing the energy required
for movement after assembly. Research on P. aeruginosa motility in the literature has shown
that the presence of E,E-farnesol inhibits swarming motility. If the cell is less capable of
extending and moving pili twitching motility is not possible because the engine that is essential
for movement has run out of gas (O’Toole, 1998; Kohler, 2000; Chiang, 2005).
The importance of a decrease in twitching motility is its role in biofilm formation.
O’Toole and Kolter found in a study in 1998 that flagella and pili are very important for the
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ability of P.aeruginosa to form a biofilm. This finding is interesting in that if exposure to
farnesol is able to decrease the ability of P. aeruginosa to form functional pili and result in a
decreased ability to form a robust biofilm. In light of the data present in the literature and the
findings in this study farnesol affects the ability of P. aeruginosa to extend and retract pili, thus
decreasing motility.

OprF
The proteomics data from the exposure of P. aeruginosa to 25 µM of E,E-farnesol did
result in the decreased abundance of OprF precursors within the cytosol and also the
peptidoglycan-associated proteins that form the channel within the membrane. This finding
suggests that the entire complex that forms the OprF porin was present at a lower abundance.
The major physiological role of OprF in P. aeruginosa is as a major non-specific surface porin.
This porin is homologous to the major porin OmpF in Escherichia coli. Interestingly, this
protein is larger than that of OmpF however diffusion rates through this porin in P. aeruginosa
are much slower. This is due to the ability of this protein to exist in two different conformations
that are temperature sensitive (Sugawara, 2006).
There could be several implications for how and why E,E-farnesol would influence the
abundance of OprF. One major theory is that by decreasing the abundance of OprF it is possible
to make the cell membrane and cell-wall less stable. The physiological experiment performed in
this study to test the effect of growth under osmotic stress (Table 9) was performed to determine
if a decreased abundance of OprF could impact the ability of the cell to resist osmotic stress and
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undergo lysis. The results indicated that there was no significant difference in the ability of P.
aeruginosa cells grown in the presence or absence of 250 µM E,E-farnesol to have growth
affected by osmotic stress. In the literature farnesol has not been shown to impact the growth or
survivability of P. aeruginosa, so even under osmotic stress the cells are still viable. In 2002,
Hassett, et al reported that OprF mutants that completely lacked OprF did show susceptibility to
osmotic stress when grown in low osmolarity medium. This finding suggests that although E,Efarnesol was shown to decrease the abundance of OprF did not affect the ability to withstand
osmotic stress.
The ability of E,E-farnesol to influence the cell membrane in gram-positive bacteria has
been shown in studies performed with Staphylococcus aureus. Figure 25A demonstrates the
ability of E,E-farnesol to inhibit the formation of biofilm in S. aureus that is proportionally
related to the dose of E,E -farnesol. Figure 25B demonstrates the ability of E,E -farnesol to
disrupt the cell membrane. Increased uptake of ethidium bromide under exposure to greater
concentrations of E,E -farnesol suggests a destabilization of the cell membrane. Figure 26
demonstrates the ability of E,E -farnesol to non-specifically enhance a broad range of antibiotic
classes partially thought to be due to the destabilization of the membrane and a disruption of the
transport mechanisms used to export antibiotics once they have entered the cell or the ability of
large antibiotic molecules to better permeate inside the cell.
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Figure 26: Biofilm formation of S. aureus and uptake of ethidium bromide when exposed
to E,E -farnesol.

Volume of farnesol in µM

Figure 26: Uptake of ethidium bromide and biofilm formation of S. aureus when grown in the presence of
varying concentrations of E,E-farnesol. (Source: Jabra-Rizk, et al., 2006)
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Figure 27: Antibiotic susceptibility patterns when S. aureus grown in presence of E,Efarnesol

Figure 27: Patterns of antibiotic susceptibility when S. aureus is grown in the presence of varying
concentrations of tt-farnesol. (Source: Jabra-Rizk, et al., 2006)

To test if exposure to E,E-farnesol could affect antibiotic susceptibility in P. aeruginosa a
minimum inhibitory concentration assay was performed with Tobramycin (Table 12). The
parameters of the assay tested whether the presence of farnesol in the growth medium and
antibiotic could decrease the dose necessary to prevent growth of Pseudomonas. The results
presented in this study did show that exposure to 250 µM E,E-farnesol did decrease the dose
necessary for Tobramycin to inhibit growth, as determined by optical density. This assay also
showed interesting in colonal morphology in doses of Tobramycin just before complete
inhibition. In Figure 24, the cells of P. aeruginosa that were exposed to farnesol demonstrated
string like structures and were not condensed. One potential reason for this finding is that
communication was disrupted and the cells could not orient themselves in a more defensive
position. With the cells in a more diffuse orientation it would be possible for more Tobramycin
to reach more cells and exhibit an effect. The role that farnesol played in increasing antibiotic
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susceptibility could be due to two reasons. The first would be an alteration in permeability of the
membrane allowing more of the antibiotic to enter the cell and exert an effect. The second
possibility would be that the ability of the cells to communicate were altered so that it was not
possible to form a condensed morphology and the number of cells that were exposed to the
antibiotic was greater. In Figure 25, there was not farnesol present and the cells formed a tight
cluster that would allow fewer cells to be in contact with the tobramycin.
OprF has also been shown in the literature to affect the ability of P. aeruginosa to perform
surveillance of the activation status of the host immune system. This protein is able to bind to
interferon-gamma located outside the cell that is secreted by activated T-cells. Wu et al. reported
this finding in 2005 where it was shown that OprF in P. aeruginosa has a role in binding
Interferon gamma (IFN-γ) that is secreted by activated T-cells in the human host. Once OprF
binds IFN-γ, a currently undetermined signaling cascade occurs that leads to the induction of
genes resulting in production of proteins and secondary metabolites critical to the infection
process, for example pyocyanin (Figure 28). A hypothesis to explore based on the results of this
study is to test the ability of E,E-farnesol to prevent the response of P. aeruginosa to IFN-γ by
measuring quorum- sensing related gene expression and pyocyanin production.
The significance of a reduction in OprF in P. aeruginosa exposed to a fungal quorum
sensing compound is the potential to reduce the ability of P. aeruginosa to prepare itself for
attack by the human host. It is possible to hypothesize that exposure to farnesol has the ability to
diminish the virulence of P. aeruginosa by decreasing its ability to sense activation of the host
immune system and response by secreting pyocyanin.
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Figure 28: Schematic for proposed role of OprF in sensing activation of t-cells by the
detection of IFN-gamma.

Figure 28: Source (Wagner, et al., 2006) Quorum sensing system and possible role of OprF in
the detection of IFN-gamma released from activated T-cells.

The role of OprF within the anaerobic biofilm, which is of great importance to the CF lung
infection model, is believed to play a role as a redundant transporter of nitrate and nitrite that
does not fall into the classical nitrate transporter category. A second possible function of OprF
within the CF lung infection model that was determined using OprF mutants was its role in
stabilizing the cell wall. It was found that OprF mutants did not form a biofilm within CF
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mucous that was as robust as the wild-type. One theory was that the lack of OprF allowed for
the peptidoglycan to become unstable. This was further illustrated by the reduced growth in low
salt environments where the cell wall would have been placed under osmotic pressures that lead
to cell lysis (Hassett, et al., 2002). Data from the osmotic stress assay (Table 9) did not
demonstrate any delay in growth or decrease in growth rate in P. aeruginosa cells exposed to
E,E-farnesol as compared to the control which did not have exposure to E,E-farnesol.
It was also shown that the OprF mutant exhibited poor NIR activity, which is thought to
recruit normal OprF in the anaerobic biofilm. Although not fully characterized, it is believed that
OprF may play a role in denitrification and the maintenance of the global nitrogen cycle (Hassett,
et al., 2002). The importance of OprF to the ability of PA to form biofilms under anaerobic
conditions was determined using proteomic analysis that revealed in an anaerobic biofilm model
the abundance of OprF increased approximately 40 fold as compared to the aerobic biofilm. It
was also found that in chronically infected CF patients there was an increase in the titer of OprF
antibodies. OprF is a surface-exposed protein that holds great promise as a viable drug target to
affect difficult to treat anaerobically growing P. aeruginosa cells.
The protein OprF has been implicated in several physiological functions in P. aeruginosa
that relates to virulence and attachment. This protein holds much promise for future areas of
research to identify new methods to combat infection with this organism. One major important
factor of OprF is its candidate as a vaccine target for P. aeruginosa infections (Price, et al.,
2001). This protein is continually presented on the outer surface of the cell and does not exhibit a
great deal of variation between strains. OprF has also been implicated in its role for allowing P.
aeruginosa to adhere to lung epithelial surfaces (Azghani, et al., 2002). This is a significant
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finding because the ability of farnesol to influence attachment to inanimate surfaces has been
tested in multiple studies and the result has consistently been that no effect was seen. A model
system could be used to mimic an epithelium and the ability of farnesol to affect attachment to
this surface could be tested. The results presented in this study provide evidence that farnesol
could decrease the ability of P. aeruginosa to attach to an epithelial surface since it decreases the
abundance of OprF.

Summary and Future Directions
The proteins that were identified in this study from P. aeruginosa showed a change in
abundance in response to exposure to E,E-farnesol. ATPase PilB and Flagellin B have a clear
role in motility. The importance of motility mediated by the flagella and the pili have
documented roles in initiating biofilm formation. The results in this study suggest that there is a
decrease in both of these proteins and could potentially affect the ability of P. aeruginosa to
form a biofilm when in contact with a variety of surfaces. One future direction will be to
determine the ability of P. aeruginosa exposed to E,E-farnesol to attach to different surfaces
including medical devices and epithelial surfaces as mediated by the pili and flagella.
The direct role of porins in moderating quourm sensing and the ability of bacteria to
detect activation of the host immune system in P. aeruginosa is a developing area of research
that is gaining greater understanding. Documented interactions between OprF and interferongamma produced by the human adaptive immune system illustrate the complexity of the
interaction between bacteria and the human host. Future directions to better determine the role
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that exposure to E,E-farnesol could have include performing assays where P. aeruginosa is
exposed to both E,E-farnesol and interferon-gamma to measure the level of activation of quorum
sensing regulated genes and measure the degree of production of virulence factors that are
regulated by those genes.
Proteins identified in this study that were shown to change in abundance upon exposure to
E,E-farnesol have not been directly linked to biofilm formation and quorum sensing as
documented in the scientific literature. However, additional experiments are needed to confirm
their peripheral role in these processes. Potential experiments include constructing mutants that
lack enzymes such as GMP synthase and dihydrolipoamide dehydrogenase to determine if
production of quorum sensing regulated virulence factors are affected. These experiments could
potentially provide a targeted approach to find the role that these enzymes play, since they are
members of larger enzymatic complexes that play multiple roles in the cell for central and
secondary metabolism.
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Protocol: Buffers and Reagents for 2D DIGE proteomics
Protocol: Cell Lysis and Crude Protein Extract
Protocol: First-dimension strip reswelling for cup or paper bridge loading
Protocol: First-dimension strip reswelling for in-gel rehydration
Protocol: Casting Analytical Gels
Protocol: Casting Preparative Gels
Protocol: Pyruvate Dehydrogenase Assay
Protocol: C. elegans Virulence Assay

Protocol : Buffers and Reagents

Stock solutions
0.75% acetic acid – 4L
____4L ddH2)
____30ml acetic acid
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1% Contrad 70 – 20L
____200ml Contrad 70
____20L ddH2O

1.0M magnesium acetate – 50ml
____add 10.73g MgAcetate to 30ml ddH20
____make up to 50ml and filter into autoclaved cent bottle

10% SDS – 250ml
____25g SDS to 200ml ddH2O
____make up to 250ml and filter into clean, rinsed bottle

1.0M Tris, not pH’d – 100ml
____add 12.1g Tris to 80ml ddH2O
____make up to 100ml and filter into clean, rinsed bottle
____store at 4°C

1.0M Tris, pH 8.0 – 500ml
____add 60.6g Tris to 400ml ddH20
____pH to 8.0 with concentrated HCl
____make up to 500ml and filter into clean, rinsed bottle
____store at 4°C
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1.5M TrisCl, pH 8.8 – 2L
____1.5L ddH2O into rinsed flask
____363g Tris
____pH to 8.8 with concentrated HCl
____make up to 2L and filter into clean, rinsed 2L bottle
____store at 4°C

Sample preparation
10mM Lysine – 10ml
____10ml ddH2O
____18mg lysine (MW 182.6)
____filter into sterile tube and store at 4°C.

Lysis buffer #1 (30mM Tris, 7M urea, 2M thiourea, 4% CHAPS, Complete) – 25ml
____make 50ml 8M urea, 2.3M thiourea
____24ml ddH20
____24g urea
____9g thiourea
____make up to 50ml with ddH2O
____add 500mg amberlite and stir for 1 h
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____filter into clean, rinsed bottle
____22 ml deionized urea/thiourea solution
____750 ul 1M Tris, not pH’d
____150 ul protector reagent (or 250 ul nuclease mix for #2)
____3 min-Complete tablets (or 500 ul protease inhibitor for #2)
____1g CHAPS
____pH to 8.6 with HCL
____make up to 25 ml
____1ml aliquots and store at -70°C

2X Lysis buffer (7M urea, 2M thiourea, 4% CHAPS, 2% DTT, 2% IPG) – 5 ml
____4.4 ml urea/thiourea solution
____200 mg CHAPS
____100 mg DTT (or 8 mg for Destreak rehydration solution)
____100 µl IPG 3-11NL
____make up to 5 ml, aliquot 500 ul, and store at -70°C

Up to 150 ul diluent for cup loading and destreak (7M urea, 2M thiourea, 4% CHAPS, 0.1%
DTT, 1% IPG 3-11NL)
____4.4 ml urea/thiourea solution
____200 mg CHAPS
____4 mg DTT
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____50 ul IPG 3-11NL
____make up to 5 ml, aliquot 500 ul, store at -70°C

1st dimension
Rehydration buffer (7M urea, 2M thiourea, 4% CHAPS, 0.4% DTT, 1% IPG)
____22 ml urea/thiourea solution
____1g CHAPS
____100 mg DTT
____ 250 ul IPG 3-11NL
____make up to 25 ml and store 1 ml aliquots at -70°C.

Casting
Bind–silane working solution (prepare fresh) – 10 ml
____8 ml 200 proof ethanol
____1.8 ml ddH2O
____200 ul glacial acetic acid
____12.5 ul bind-silane

Monomer solution (40% T, 3% C) – 1L
____add 12 g Bis to 1L 40% acrylamide in the supplied bottle
____dissolve and store at 4°C
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Gel solution (12.5%) – 900ml
____280 ml 40% monomer solution (12% 270ml)
____225 ml 1.5M TrisCl pH8.8
____382 ml ddH2O (12% 392)
____9 ml 10% SDS
____450 ul TEMED
____mix and degas for at least 10 min
____add 3.6 ml 10% APS

Gel solution (12.5%) – 450 ml
____140 ml 40% monomer solution
____113 ml 1.5M TrisCl, pH8.8
____191 ml ddH2O
____4.5 ml 10% SDS
____225 ul TEMED
____mix and degas for 20 min
____1.8 ml 10% APS

Gel solution (12.5%, Protogel) – 450 ml
____188 ml Protogel monomer solution
____113 ml TrisCl pH 8.8
____142 ml ddH2O
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____4.5 ml SDS
____225 ul TEMED
____mix and make 10% APS (2ml ddH20 and 200mg APS)
____add 1.8 ml 10% APS prior to pouring

Displacing solution (0.375M TrisCl pH 8.8, 50% glycerol, 0.002% bromophenol blue) – 120 ml
____20 ml ddH20
____30 ml 1.5M TrisCl pH 8.8
____70 ml glycerol
____240 ul 1% bromophenol blue

Water saturated butanol – 110 ml
____100 ml butanol
____10 ml ddH20

2nd dimension
Agarose sealing solution (0.5% agarose and 0.01% bromophenol blue in electrophoresis buffer)
– 50ml
____50 ml 1X electrophoresis
____250 mg
____5 mg bromophenol blue
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2X SDS running buffer ([final] 15mM Tris, 192mM glycine, 0.2% SDS) – 10L
____transfer 1.5L ddH20 to flask
____add 60.5 g Tris
____add 288 g glycine
____add 40 g SDS
____dissolve and make up to 2 L
____add 2 L concentrate to 8 L ddH2O in 15 L carboy and store at room temp

Equilibration stock solution (50mM TrisCl pH 8.8, 6M urea, 30% glycerol, 2% SDS, 0.01%
bromophenol blue – 1L
____250 ml ddH2O
____352 ml glycerol
____34 ml 1.5M TrisCl pH 8.8
____360 g urea
____dissolve and make up to 1L
____20 g SDS and dissolve
____100 mg bromophenol blue
____50 ml aliquots in 50ml centrifuge tubes and store at -20C

Protocol: Cell Lysis and Crude Protein Extract
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Crude protein extract

1) Remove cell pellets and solubilization buffer (1 tube per pellet) from -80°C and allow
solubilization buffer to thaw at room temperature. Solubilization buffer should be
vorrtexed until all components are fully in solution. No precipitated urea should be
visible. The cell pellets should be placed in an ice bucket until ready for use.

2) Remove one cell pellet from ice bucket and add one aliquot of solubilization buffer to the
cell pellet tube.

3) Vortex the slurry until the pellet is fully in suspension.

4) Transfer slurry to sonication vessel, such as 15ml sterile Falcon tube, and incubate on ice
for five minutes.

5) Clean sonication tip with three rounds of ethanol and water. Set up beaker on a stir plate
with ice water to submerge the sonication vessel into.
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6) Fix probe into sonication vessel. The tip should be at the center of the vessel and at the
midpoint of the sample slurry.

7) Sonicate sample for a total process time of two minutes. The cycle should be one second
pulse on and .5 seconds pulse off time. Pause the sonication every 30 seconds to allow
the sample to cool on ice for approximately one minute. Replace ice to the ice bath
beaker as needed.

8) Transfer lysate to a low-bind Eppendorf tube and place the tube on ice until all samples
have been processed.

9) Place samples into an Eppendorf centrifuge and spin at maximum speed (13,500 RPM)
for ten minutes.

10) Transfer clarified lysate to fresh low-bind Eppendorf tube.

144

Protocol: First-dimension Strip Reswelling for Cup or Paper-bridge Loading

IPG strip rehydration with reswelling tray for cup or paper-bridge loading
only

1) Using a toothbrush, clean the reswelling tray with IPG detergent (or other non-ionic
detergent). Rinse thoroughly with ddH20 and air dry (if needed, use crewipes to dry).

2) Remove appropriate amount of Destreak rehydration solution from -20°C. Bottle contains
3 ml of solution and should be thawed at room temperature. A total of 450 µl is required
per well per strip. Once thawed, vortex vigorously until white solid urea dissolves.

3) Add IPG buffer (or other ampholytes) to 0.5% v/v (15ul to 3ml, 60ul to 6ml).
Note: Ampholyte range should match that of the strip. However, many prefer 3-11NL
ampholytes when using 3-7NL or 4-7 strips.

4) For right –handed persons, orient the reswelling tray so that the acidic (+) end is to the
left. Acidic end has the little circular well. Pipet 450 ul of rehydration solution along the
length of the channel. Do no go beyond the length of the strip.

5) Remove one strip at a time from the packaging. Place the remaining strips in the freezer
until ready for use. Once the packaging is opened remove the strip with curved forceps.
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Then use fingers to separate the protective plastic strip from the gel. Once the two have
separated use the forceps to grasp the cover strip. Hold onto the back strip with fingers.
Once protective strip is removed grasp the back strip (with the gel) with the forcepts.
Ensure that the gel side of the strip is facing down when placed in the reswelling tray.
Introduce the basic end first into the channel at the furthest point where the Destreak
solution was added. Then gradually introduce the strip into the channel making sure that
the Destreak solution is evenly distributed along the strip. The acidic end should be over
the small well holes.

6) Cover each strip with 3.4 ml of Drystrip cover fluid (mineral oil).

7) Insert cover and balance with black knobs and balance indicator in the reswelling tray.

8) Incubate strips for 20-30 hours at room temp.

Protocol: Casting Analytical Gels

(Analytical: gels not bound to plate; used for imaging only)

14 gels in large gel box: for smaller gel box (6 gels) use volumes in parenthesis.
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Reagent prep:

Gel solution (12.5%) – 900ml; mix in flask with spout for vacuum tube
____280 ml (147ml) 40% monomer solution
____225 ml (117.5ml) 1.5M TrisCl pH8.8
____382 ml (196ml) ddH2O
____9 ml (4.7ml) 10% SDS
____450 µl (188µl) TEMED
____mix and degas for at least 10 min ( place clean mouse pad over mouth, attach
vacuum tube to spout and turn on. Vacuum is adequate when mouse pad dimples into mouth of
flask)

10% APS – 4ml
____add 1g APS to 9.6ml ddH2O
____add 9.4 ml (4.7 ml) fresh 10% APS (add immediately prior to pouring)

Displacement solution – 120 ml
____20 ml ddH20
____30 ml 1.5M TrisCl pH 8.8
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____70 ml glycerol
____240 ul 1% bromophenol blue

Protocol
1) Clean plates and dry with Kimwipes or allow to air dry
2) Prepare solutions
3) Load gel box and level. Place thin spacer first in the box, push as far as possible to the
left of the box with the “wonder wedge.” Then place the back plate with the spacer and
push to the left. Finally, place the top plate and push as far to the left. Place another thin
spacer. Repeat this until six complete sandwiches are in place. Then fill the remainder of
the box with the thick spacers until they are flush with the edge of the box. Place gel-seal
around the perimeter of the caster on the grey gasket. Gently smear with single gloved
finger. Place the front of the caster onto the back. Gently tighten the screws on the
bottom of the caster. Place the red and black clamps, and then fully tighten the screws on
the bottom. Ensure that the seal is tight (the gel-seal will spread).
4) Add 10% APS to gel solution and mix gently; prevent formation of bubbles (There is
SDS in this solution!!!)
5) Pour gel solution directly from the flask slowly until 1cm below top of front plate Add
displacement solution to large gel caster only
6) Overlay each gel with 1ml water saturated butanol with a 1ml pipette. Be sure to
introduce between the plates of the gel sandwich. Drag pipette smoothly from one end of
the sandwich to the other. Be consistent in application for each sandwich!
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7) Allow to polymerize for at least 1.5 hours
8) Remove sandwiches, trim excess acrylamide, rinse thoroughly with double deionized
water, and lay clean gels on plastic wrap. Fold plastic wrap over the bottom half of the
gel to create a pocket. Then add gel storage solution (approximately 10 ml total) to the
bottom, the notch on the top and the sides. Fold plastic wrap to enclose all of the gel
solution.
9) Allow to polymerize overnight at room temperature lying horizontally. Then in the
morning place at 4°C until ready for use. Make sure that the gel is moist and that the gel
storage solution was not lost. If they gels dry out they are useless.

Protocol: Casting Preparative Gels

(preparative: gels bound to plate. To be used for spot picking and MS
analysis)

1) Prepare 2L of 1% HCL
2) Pour 1.5L 1% HCL into staining bucket
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3) Insert plates to have gels bound to (decide if top or back plate. Must be consistent!!!)
stack carefully on top of each other
4) Incubate at 30 rpm for 2h
5) Wash top plates with 1% Decon Labs detergent (Do not use excessive detergent or timethe plates will become etched and ruined). Rinse with deionized water, then double
deionized water and shake off excess water and leave to dry protected from dust
contamination
6) Repeat (5) with acid-treated plates
7) Prepare 4 ml bind solution per gel
Bind–silane working solution – 10 ml
____8 ml 200 proof ethanol
____1.8 ml ddH2O
____200 ul glacial acetic acid
____12.5 ul bind-silane
8) Place dried plate on clean surface with face to have gel attached facing up.
9) Evenly spread 4 ml bind solution over each plate and allow Bind solution to cure before
covering. Then cover to protect from dust and let sit for one hour.
10) Place markers two cm away from spacers and 10.5 cm from bottom and allow plates to
sit for an additional hour. When placing the markers be sure to be consistent on each
plate. If placing markers on the top plate make sure to accommodate for the space that
the spacers on the back plate will take up. Make a template to follow to ensure that the
markers are placed consistently.
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11) Prepare solutions according to Casting (analytical) protocol
12) Wipe treated plates with 200 proof ethanol before loading caster and let them sit several
minutes before placing in the caster. The bind solution will volatize and stick to the
opposite plate if not allowed to vent properly. If binding to the top plate make sure that
the face with the bind solution is placed on the inside of the gel sandwich (facing the
back plate).
Protocol: Pyruvate Dehydrogenase Assay
Read absorption at 500 nm at 25℃
Reagents:
Reaction solution: (2.5 mM NAD, 0.2 mM thiamine pyrophosphate, 0.1 mM Coenzyme A, 0.3
mM DTT, 1 mM Magnesium chloride, .6 mM INT) Make up in 10X solution to accommodate
small masses of additives. Make reaction solution up to a total volume of 10 ml
First add 7 ml of double deionized water then add the following components
17 mg of NAD (MW 685.41)
.9 mg of Thiamine Pyrophosphate (MW 460.77)
.767 mg of Coenzyme A (MW 767.53)
.462 mg of DTT (MW 154.25)
.952 mg of Magnesium Chloride (MW 95.21)
3.03 mg of INT (MW 505.70)
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Then store the reaction solution a 4℃ until ready for use.
Make up fresh pyruvate (MW 110.04) prior to use. Start with a 4X solution of 5mM pyruvate by
adding .55 mg into 10 ml of double deionized water.
Cell prep:
Disrupt the cells to be assayed into appropriate lysis buffer (50 mM PBS) and centrifuge at
10,000 x g for 10 minutes to pellet any cellular debris. Collect the supernatant and discard the
pellet. Remove 10 µl to use in quantification of the amount of protein present in the lysate.
Adjust the final concentration of all samples to 1 µg/µl with 50 mM PBS.
Add the same volume of crude enzyme extract into each reaction vial (3 replicates per sample).
Then take a base line OD before the pyruvate is added. This value will be subtracted from each
sample to determine the difference in slope between the control and experimental conditions.
To start the reaction mixture add an appropriate volume of 5 mM pyruvate (MW 110.04) to start
the reaction. Then read the OD at 500 nm at 25℃

In order to obtain the correct concentration of reaction mixture, pyruvate solution, and protein
concentration make up the solution in the following manor:
Total volume in each reaction vial 1.5 ml
Make up a 10x solution of the reaction mixture and add 150 µl
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Then make up a 4x solution of pyruvate and add 375 µl
Then calculate the volume of crude sample needed to add the same concentration to each vial x
and subtract from (150 + 375 = 525). Take that value and add that volume of water
525 - (X µl of crude lysate)= vol. of water
* This gives you 975 ml to work with
The goal is to have the total volume in the vial at 1.5 ml
Then remove 300 µl and assay in the Victor at 490nm and take 1 ml and assay in the Turner at
500nm.
Protocol overview:
1. disrupt cells
2. quantify and adjust concentration to 1 µg/µl with 50 mM PBS
3. Add lysate and reaction mixture without pyruvate and take OD
4. Add pyruvate and measure color change
5. Calculate the difference between the two slopes (with and without pyruvate) to de termine
the rate of activity
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Protocol: C. elegans Virulence Assay
Assay for fast killing (based on high salt medium use high osmolarity PGS media). The fast
killing assay should be scored 8 hours post inoculation.
Grow P. aeruginosa and E. coli 0P50 control overnight in LB medium to an approximate OD600
nm of 1.
Inoculate assay Petri plates (5.5 cm) with 10 µl of cell suspension and spread over plate with
glass spreader incubate for 16 hours at 37℃ and 24 hours at 25℃
Seed plate with 20-30 L4 stage C. elegans once seeded incubate at 25℃
Score after 8 hours (% live organisms compared to survival on the E. coli 0P50 control strain.
Considered dead when touched by a metal probe and no response)
Assay for slow killing (based on low salt medium use NG medium) follow protocol above but
score after 3 days.

Media
NG: Nematode growth medium source US biologicals

Agar 17.5 g/L
Sodium Chloride 3.0 g/L
Peptone 2.5 g/L
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Cholesterol 0.005 g/L
Total:
23.005g/L

500g makes 21.7 liters
Directions per Liter:
Dissolve 23.005 grams per liter of distilled/deionized (DDI) water. Heat with stirring
until completely solubilized. Adjust pH as necessary. Dispense into appropriate
containers. Loosen caps or cover with foil. Autoclave for 15 minutes at 121ºC (15psi).
Cooling the N1000 solution:
Place the sterile N1000 solution into the water bath
N1000 solution needs 31 hour to cool to the desired temperature (58°C). If the media is
not properly cooled when the CaCl2, MgSO4 and K2PO4 are added, crystals will form in
the agar.
Further preparing the media:
Once the N1000 solution has cooled to 58°C, place flask(s) onto stir plate(s). Maintain
temperature at 58°C Add the following:
a) 1M K2PO4, pH 6.0: 25ml/liter N1000 solution
b) 1M CaCl2: 1ml/liter N1000 solution
c) 1M MgSO4: 1ml/liter N1000solution
Allow the solution to mix for five minutes before starting to pour plates to ensure that a
155

homogeneous mixture has been achieved.
Storage and Stability:
Store powdered media at RT. Opened bottles should be capped tightly and kept in a dark,
low humidity environment. Prepared media should be kept at 4°C and used within a short
period of time
PGS medium per Liter

1% Bacto peptone
1% NaCl
1% glucose
0.15M sorbitol
1.7% Bacto agar

LB medium
* grow on 5 g NaCl in place of 10 g NaCl
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